<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006734.pub2" GROUP_ID="HIV" ID="154307030514522903" MERGED_FROM="" MODIFIED="2009-11-10 23:21:44 +0100" MODIFIED_BY="Tara Horvath" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.21" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2009-11-10 23:21:44 +0100" MODIFIED_BY="Tara Horvath">
<TITLE MODIFIED="2008-11-07 15:33:22 -0800" MODIFIED_BY="Tara Horvath">Interventions for preventing late postnatal mother-to-child transmission of HIV</TITLE>
<CONTACT MODIFIED="2009-11-10 23:21:44 +0100" MODIFIED_BY="Tara Horvath"><PERSON ID="17315" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Tara</FIRST_NAME><LAST_NAME>Horvath</LAST_NAME><POSITION>Assistant Managing Editor, Cochrane HIV/AIDS Group</POSITION><EMAIL_1>thorvath@psg.ucsf.edu</EMAIL_1><URL>http://www.igh.org/Cochrane</URL><ADDRESS><DEPARTMENT>Global Health Sciences</DEPARTMENT><ORGANISATION>University of California, San Francisco</ORGANISATION><ADDRESS_1>50 Beale Street</ADDRESS_1><ADDRESS_2>Suite 1200</ADDRESS_2><CITY>San Francisco</CITY><ZIP>94105</ZIP><REGION>California</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+415-597-8208</PHONE_1><FAX_1>+415-597-8299</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-11-10 23:21:44 +0100" MODIFIED_BY="Tara Horvath"><PERSON ID="17315" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Tara</FIRST_NAME><LAST_NAME>Horvath</LAST_NAME><POSITION>Assistant Managing Editor, Cochrane HIV/AIDS Group</POSITION><EMAIL_1>thorvath@psg.ucsf.edu</EMAIL_1><URL>http://www.igh.org/Cochrane</URL><ADDRESS><DEPARTMENT>Global Health Sciences</DEPARTMENT><ORGANISATION>University of California, San Francisco</ORGANISATION><ADDRESS_1>50 Beale Street</ADDRESS_1><ADDRESS_2>Suite 1200</ADDRESS_2><CITY>San Francisco</CITY><ZIP>94105</ZIP><REGION>California</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+415-597-8208</PHONE_1><FAX_1>+415-597-8299</FAX_1></ADDRESS></PERSON><PERSON ID="14106" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Banyana</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Madi</LAST_NAME><POSITION>Technical adviser: HIV and AIDS policy development and Harmonisation</POSITION><EMAIL_1>banyana@bcmadi.com</EMAIL_1><ADDRESS><DEPARTMENT>HIV and AIDS Unit</DEPARTMENT><ORGANISATION>SADC secretariat</ORGANISATION><ADDRESS_1>Private Bag 0095</ADDRESS_1><CITY>Gaborone</CITY><COUNTRY CODE="BW">Botswana</COUNTRY></ADDRESS></PERSON><PERSON ID="95DE48A682E26AA200D45F89F1ED5CC6" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Irene</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Iuppa</LAST_NAME><POSITION>Research Assistant</POSITION><EMAIL_1>iiuppa@psg.ucsf.edu</EMAIL_1><ADDRESS><DEPARTMENT>Global Health Sciences</DEPARTMENT><ORGANISATION>University of California, San Francisco</ORGANISATION><CITY>San Francisco</CITY><ZIP>94105</ZIP><REGION>California</REGION><COUNTRY CODE="US">USA</COUNTRY></ADDRESS></PERSON><PERSON ID="7034" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Gail</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Kennedy</LAST_NAME><POSITION>Managing Editor, Cochrane HIV/AIDS Group</POSITION><EMAIL_1>gkennedy@psg.ucsf.edu</EMAIL_1><URL>http://www.igh.org/Cochrane</URL><ADDRESS><DEPARTMENT>Global Health Sciences</DEPARTMENT><ORGANISATION>University of California, San Francisco</ORGANISATION><ADDRESS_1>50 Beale Street</ADDRESS_1><ADDRESS_2>Suite 1200</ADDRESS_2><CITY>San Francisco</CITY><ZIP>94105</ZIP><REGION>CA</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 415 597 9373</PHONE_1><FAX_1>+1 415 597 8299</FAX_1></ADDRESS></PERSON><PERSON ID="7065" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>George</FIRST_NAME><MIDDLE_INITIALS>W</MIDDLE_INITIALS><LAST_NAME>Rutherford</LAST_NAME><POSITION>Co-ordinating Editor, Cochrane HIV/AIDS Group</POSITION><EMAIL_1>GRutherford@psg.ucsf.edu</EMAIL_1><ADDRESS><DEPARTMENT>Global Health Sciences</DEPARTMENT><ORGANISATION>University of California, San Francisco</ORGANISATION><ADDRESS_1>50 Beale Street</ADDRESS_1><ADDRESS_2>Suite 1200</ADDRESS_2><CITY>San Francisco</CITY><ZIP>94105</ZIP><REGION>CA</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 415 597 9108</PHONE_1><FAX_1>+1 415 597 8299</FAX_1></ADDRESS></PERSON><PERSON ID="14125" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jennifer</FIRST_NAME><MIDDLE_INITIALS>S.</MIDDLE_INITIALS><LAST_NAME>Read</LAST_NAME><SUFFIX>MD, MS, MPH, DTM&amp;H</SUFFIX><EMAIL_1>readj@exchange.nih.gov</EMAIL_1><ADDRESS><DEPARTMENT>Pediatric, Adolescent, and Maternal AIDS Branch, Center for Research for Mothers and Children</DEPARTMENT><ORGANISATION>Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health</ORGANISATION><ADDRESS_1>Executive Building, Room 4B11F, 6100 Executive Boulevard MSC 7510</ADDRESS_1><CITY>Bethesda</CITY><ZIP>20892-7510</ZIP><REGION>MD</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>301 435-6872</PHONE_1><FAX_1>301 496-8678</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-12-03 11:14:22 -0800" MODIFIED_BY="Tara Horvath">
<UP_TO_DATE>
<DATE DAY="20" MONTH="9" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="7" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="12" MONTH="11" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2009"/>
</DATES>
<WHATS_NEW MODIFIED="2009-11-09 12:38:52 -0800" MODIFIED_BY="Tara Horvath">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-11-09 12:38:52 -0800" MODIFIED_BY="Tara Horvath">
<DATE DAY="9" MONTH="11" YEAR="2009"/>
<DESCRIPTION>
<P>Notice that this review will be split, and that future updates to this review will be of a different scope.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-11-09 12:37:28 -0800" MODIFIED_BY="Tara Horvath">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-11-09 12:37:28 -0800" MODIFIED_BY="Tara Horvath">
<DATE DAY="10" MONTH="12" YEAR="2008"/>
<DESCRIPTION>
<P>Corrected one of the additional references (changed one to Safrit 2004); added author contributions; made a few subtle edits for clarity.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2008-11-07 15:21:03 -0800" MODIFIED_BY="Tara Horvath">
<INTERNAL_SOURCES MODIFIED="2008-11-07 15:21:03 -0800" MODIFIED_BY="Tara Horvath">
<SOURCE MODIFIED="2008-10-24 16:41:02 -0700" MODIFIED_BY="Tara Horvath">
<NAME>Global Health Sciences, University of California, San Francisco</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-11-09 12:36:55 -0800" MODIFIED_BY="Tara Horvath">
<SUMMARY MODIFIED="2008-11-07 14:51:01 -0800" MODIFIED_BY="Tara Horvath">
<TITLE MODIFIED="2008-10-28 15:59:38 -0700" MODIFIED_BY="Tara Horvath">Transmission of HIV from mother to child through breast milk</TITLE>
<SUMMARY_BODY MODIFIED="2008-11-07 14:51:01 -0800" MODIFIED_BY="Tara Horvath">
<P>Mother-to-child transmission (MTCT) of HIV is the primary way that children become infected with HIV.  Such transmission can take place when the child is still in the mother&#8217;s womb, around the time of birth, or through breastfeeding after birth.  Hundreds of thousands of children are infected this way every year, with most of them in developing countries.  Major progress has been made in preventing MTCT when the baby is still in the mother&#8217;s womb, or around the time the baby is born.  In many resource-rich settings, mothers with HIV infection are counseled not to breastfeed their children, and there are feasible and affordable alternatives to breastfeeding.  However, in parts of the world where the vast majority of mothers with HIV infection live, complete avoidance of breastfeeding is often not feasible (for example, because of the lack of availability of clean water and of affordable replacement feeding).  Therefore, interventions to prevent transmission of HIV infection through breast milk are urgently needed.  The authors found that, in addition to complete avoidance of breastfeeding if safe and affordable, exclusive breastfeeding (where the baby receives only breast milk) for the first few months of life helps prevent transmission (as compared to breastfeeding supplemented by feeding the baby other liquids or solids).  Another intervention, giving the baby an anti-HIV medicine (antiretroviral) while breastfeeding, decreases the risk of transmission of HIV from mother to child. Implementation of such interventions, as well as developing more and better interventions, is essential.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-12-03 10:56:31 -0800" MODIFIED_BY="Tara Horvath">
<ABS_BACKGROUND MODIFIED="2008-10-20 12:59:16 -0700" MODIFIED_BY="Tara Horvath">
<P>Worldwide, mother-to-child transmission (MTCT) of human immunodeficiency virus type 1 (HIV) represents the most common means by which children acquire HIV infection.  Efficacious and effective interventions to prevent <I>in utero</I> and intrapartum transmission of HIV infection have been developed and implemented.  However, a large proportion of MTCT of HIV occurs postnatally, through breast milk transmission. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-11-07 14:34:40 -0800" MODIFIED_BY="Tara Horvath">
<P>The objectives of this systematic review were to collate and assess the evidence regarding interventions to decrease late postnatal MTCT of HIV, and to determine the efficacy of such interventions in decreasing late postnatal MTCT of HIV, increasing overall survival, and increasing HIV-free survival. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-11-07 14:35:03 -0800" MODIFIED_BY="Tara Horvath">
<P>Electronic searches were undertaken using PubMed, EMBASE and other databases for 1980-2008.  Hand searches of reference lists of pertinent reviews and studies, as well as abstracts from relevant conferences, were also conducted.  Experts in the field were contacted to locate any other studies.  The search strategy was iterative.    </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-11-07 14:35:23 -0800" MODIFIED_BY="Tara Horvath">
<P>Randomized clinical trials assessing the efficacy of interventions to prevent MTCT of HIV through breast milk were included in the analysis.  Other trials and intervention cohort studies with relevant data also were included, but only when randomization was not feasible due to the nature of the intervention (i.e., infant feeding modality). </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-11-07 14:35:36 -0800" MODIFIED_BY="Tara Horvath">
<P>Data regarding HIV infection status and vital status of infants born to HIV-infected women, according to intervention, were extracted from the reports of the studies.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-12-03 10:55:39 -0800" MODIFIED_BY="Tara Horvath">
<P>Six randomized clinical trials and one intervention cohort study were included in this review.  Two trials addressed the issue of shortening the duration of (or eliminating) exposure to breast milk. In a trial of breastfeeding versus formula feeding, formula feeding was efficacious in preventing MTCT of HIV (the cumulative probability of HIV infection at 24 months was 36.7% in the breastfeeding arm and 20.5% in the formula arm [p = 0.001]), but the mortality and malnutrition rates during the first two years of life were similar in the two groups.  In a trial of early cessation of breastfeeding, HIV-free survival was similar between those children who ceased breastfeeding abruptly around four months of age and those who continued breastfeeding.  Another trial addressing vitamin supplementation found more cases of HIV infection among children of mothers in the vitamin A arm.  Efficacy for other vitamin supplements was not shown.  An intervention cohort study evaluated the risk of MTCT by six months of age according to infant feeding modality, and found increased risks of MTCT among breastfed children who also received solids any time after birth (hazard ratio = 10.87, 1.51-78.00, p = 0.018). Cumulative 3-month mortality among formula fed infants was higher than among exclusively breastfed infants (hazard ratio = 2.06, 1.00-4.27, p = 0.051). Three trials evaluated antiretroviral prophylaxis to breastfeeding infants. In one trial conducted in Botswana, mothers received zidovudine prophylaxis beginning at 34 weeks gestation and during labor, and mother and infants were randomized to receive a two-dose nevirapine regimen or placebo.  Infants were randomized to six months of breastfeeding with zidovudine prophylaxis (breastfeeding+zidovudine) or formula feeding with one month of infant zidovudine (formula+zidovudine). Mothers were instructed to initiate and complete weaning between five and six months of age. Breastfeeding+zidovudine (transmission rate = 9.0%) was not as effective as formula+zidovudine (transmission rate 5.6%) in preventing late postnatal HIV transmission (p = 0.04).  Breastfeeding+zidovudine and formula+zidovudine had comparable HIV-free survival rates at 18 months (p = 0.60). Two trials of extended infant nevirapine prophylaxis demonstrated efficacy.  In the first (data combined from trials conducted in three different countries), a six-week course of nevirapine resulted in a lower risk of HIV transmission by six weeks of age (p=0.009), but not at six months of age (p = 0.016).  In the second, mothers were counseled to breastfeed exclusively for six months and to consider weaning thereafter.  Nevirapine administration until 14 weeks of age (5.2%) or nevirapine with zidovudine until 14 weeks of age (6.4%) resulted in significantly lower risks of MTCT of HIV by 9 months of age than a control regimen of two-dose nevirapine prophylaxis (10.6%) (p &lt; 0.001).  HIV-free survival was significantly better through the age of 9 months in both extended prophylaxis groups, and through the age of 15 months in the extended nevirapine group.  </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-12-03 10:56:31 -0800" MODIFIED_BY="Tara Horvath">
<P>Complete avoidance of breastfeeding is efficacious in preventing MTCT of HIV, but this intervention has significant associated morbidity (e.g., diarrheal morbidity if formula is prepared without clean water).  If breastfeeding is initiated, two interventions 1). exclusive breastfeeding during the first few months of life;  and 2)  extended antiretroviral prophylaxis to the infant (nevirapine alone, or nevirapine with zidovudine) are efficacious in preventing transmission. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-11-09 12:36:55 -0800" MODIFIED_BY="Tara Horvath">
<BACKGROUND MODIFIED="2009-11-09 12:36:55 -0800" MODIFIED_BY="Tara Horvath">
<P>By the end of 2007, approximately 33 million people worldwide, including 2.1 million children under the age of 15 years, were living with human immunodeficiency virus type 1 (HIV) infection or acquired immunodeficiency syndrome (AIDS) (<LINK REF="REF-UNAIDS-2008" TYPE="REFERENCE">UNAIDS 2008</LINK>).  An estimated 1200 children under the age of 15 years acquire HIV infection each day (420,000 new infections/year) (<LINK REF="REF-UNAIDS-2008" TYPE="REFERENCE">UNAIDS 2008</LINK>).  The vast majority of HIV-infected children acquire the infection through mother-to-child transmission (MTCT) <I>in utero</I>, around the time of labor and delivery, or postnatally through breastfeeding (<LINK REF="REF-Read-2005a" TYPE="REFERENCE">Read 2005a</LINK>).</P>
<P>
<B>Evidence of increased mortality among children of HIV-infected mothers</B>
</P>
<P>Children born to HIV-infected mothers have high rates of mortality, regardless of their own infection status (<LINK REF="REF-Newell-2004" TYPE="REFERENCE">Newell 2004</LINK>). In a pooled analysis of randomized trials from sub-Saharan Africa, children born to mothers in the advanced stages of HIV infection were at considerably higher risk of death when compared to those of mothers who were at a less advanced stage of the disease (irrespective of the child's HIV infection status), and this association was even stronger for uninfected children (<LINK REF="REF-Newell-2004" TYPE="REFERENCE">Newell 2004</LINK>).  Also, the timing of acquisition of HIV infection was associated with mortality, as children who were infected before four weeks of age were at higher risk of death during the first 12-24 months after infection than those who acquired infection after four weeks of age (through breastfeeding). </P>
<P>
<B>Mother-to-child transmission of HIV</B>
</P>
<P>An 'umbrella review' of five Cochrane reviews recently examined the evidence for interventions for the prevention of <I>in utero</I> and intrapartum MTCT (<LINK REF="REF-Bond-2007" TYPE="REFERENCE">Bond 2007</LINK>). Two interventions have been shown to be efficacious in the prevention of MTCT of HIV during these periods:</P>
<P>Antiretroviral (ARV) prophylaxis: ARVs given to HIV-infected pregnant women and/or to their infants can prevent MTCT of HIV (<LINK REF="REF-Volmink-2007" TYPE="REFERENCE">Volmink 2007</LINK>).</P>
<P>Caesarean delivery before labor and before ruptured membranes ('elective' Caesarean section, or ECS):  Performing a caesarean section before labor and before ruptured membranes can prevent MTCT of HIV (<LINK REF="REF-Read-2005b" TYPE="REFERENCE">Read 2005b</LINK>).</P>
<P>This systematic review will analyze the evidence of interventions for the prevention of late postnatal (breastfeeding) MTCT of HIV.</P>
<P>
<B>Late postnatal MTCT of HIV (through breastfeeding)</B>
</P>
<P>In 2006, the World Health Organization reaffirmed previous recommendations for all HIV-infected mothers to receive counseling, including provision of general information about risks and benefits of various infant feeding options, and specific guidance in selecting the feeding option most likely to be suitable for their individual situation. It also called for mothers to be supported in their choices regarding infant feeding (<LINK REF="REF-WHO-2006" TYPE="REFERENCE">WHO 2006</LINK>).</P>
<P>The benefits of breastfeeding are well recognized and include significantly decreased infant morbidity and mortality rates by providing optimal nutrition, protecting against common childhood infections (such as gastrointestinal and respiratory tract infections), and promoting child spacing (<LINK REF="REF-Pebley-1986" TYPE="REFERENCE">Pebley 1986</LINK>; <LINK REF="REF-Thapa-1988" TYPE="REFERENCE">Thapa 1988</LINK>; <LINK REF="REF-Yoon-1996" TYPE="REFERENCE">Yoon 1996</LINK>; <LINK REF="REF-Cesar-1999" TYPE="REFERENCE">Cesar 1999</LINK>; <LINK REF="REF-WHO-Team-2000" TYPE="REFERENCE">WHO Team 2000</LINK>; <LINK REF="REF-Kramer-2001" TYPE="REFERENCE">Kramer 2001</LINK>). Breastfeeding is particularly important in resource-poor regions of the world, where limited access to clean water increases the risk of diarrhea if replacement feeding is used, and many mothers do not have the means to afford the costs of formula and other breast milk substitutes. However, HIV is transmitted through human milk, leading to the dilemma that the use of replacement feeding in resource-poor settings, while protecting an infant against HIV infection, also could place the same infant at risk of morbidity and mortality from other infections.</P>
<P>Moreover, mothers opting to feed their children through replacement feeding are stigmatized in many cultures, which greatly complicates adherence to a replacement-feeding regimen <U>(</U>
<LINK REF="REF-Rankin-2005" TYPE="REFERENCE">Rankin 2005</LINK>
<U>)</U>. They are often assumed to be infected with HIV, leading to HIV-associated stigma, where women may be ostracized and expelled from their families in the case of suspected HIV infection. Even in situations where an HIV-associated stigma does not exist and women have the choice to breastfeed or use replacement feeding, the supplies needed to continually conduct replacement feeding can be sporadic, compromising infant nutrition or resulting in mixed feeding. However, exclusive breastfeeding in itself can be difficult for mothers, especially for those who have responsibilities that take them away from their children during the day. In these instances, a child may receive mixed feedings, i.e., breast milk when with their mothers, and alternative feeding options when being cared for by others.</P>
<P>Shortly after the first report of transmission of HIV through breastfeeding (<LINK REF="REF-Ziegler-1985" TYPE="REFERENCE">Ziegler 1985</LINK>), the U.S. Centers for Disease Control and Prevention (CDC) recommended that HIV-infected women in the United States of America avoid breastfeeding (<LINK REF="REF-MMWR-1985" TYPE="REFERENCE">MMWR 1985</LINK>), because replacement feeding in the U.S. is safe, affordable, and culturally acceptable. The CDC and the American Academy of Pediatrics (<LINK REF="REF-AAP-1995" TYPE="REFERENCE">AAP 1995</LINK>) have continued to recommend counseling HIV-infected women in the U.S. not to breastfeed or provide their milk for the nutrition of their own or other infants. Avoidance of breastfeeding remains an important component of efforts to prevent MTCT of HIV in the U.S. (<LINK REF="REF-Read-1999" TYPE="REFERENCE">Read 1999</LINK>) and in other countries.  MTCT of HIV has been substantially decreased in the U.S. (<LINK REF="REF-Lindegren-1999" TYPE="REFERENCE">Lindegren 1999</LINK>), in Europe, and elsewhere. </P>
<P>However, in many areas of the world, especially those areas where breastfeeding is the norm and safe replacement feeding generally is not possible, the enormous and unremitting epidemic of MTCT of HIV continues (<LINK REF="REF-UNAIDS-2008" TYPE="REFERENCE">UNAIDS 2008</LINK>). Recommendations of the World Health Organization (WHO) are similar to those of the CDC, in that when replacement feeding is acceptable, feasible, sustainable, and safe, HIV-infected mothers should avoid breastfeeding altogether (<LINK REF="REF-WHO-2006" TYPE="REFERENCE">WHO 2006</LINK>).  Research efforts focused on the continuing problem of breastfeeding transmission in much of the world have yielded additional information regarding mechanisms of HIV transmission through breastfeeding, as well as the timing of and risk factors for such transmission.</P>
<P>
<B>Breastfeeding transmission of HIV </B>
</P>
<P>Over more than two decades, the understanding of MTCT of HIV through breastfeeding has increased tremendously. Beginning with the earliest clinical evidence (case reports) of breastfeeding transmission of HIV (<LINK REF="REF-Ziegler-1985" TYPE="REFERENCE">Ziegler 1985</LINK>), additional information regarding breastfeeding transmission has come from numerous descriptive, analytic epidemiologic, and laboratory studies (<LINK REF="REF-Read-2003" TYPE="REFERENCE">Read 2003</LINK>). Risk factors for transmission of HIV through breastfeeding have been identified, including the duration of breastfeeding as well as characteristics of the mother, the infant, the breast milk, and the type of breastfeeding.</P>
<P>
<U>Duration of breastfeeding</U>
</P>
<P>The contribution of breastfeeding transmission to the overall risk of MTCT of HIV, and the timing of and risk factors for breastfeeding transmission, were analyzed in an individual patient data meta-analysis of nine clinical trials of HIV-infected women and their infants, conducted in sub-Saharan Africa (<LINK REF="REF-BHITS-2004" TYPE="REFERENCE">BHITS 2004</LINK>).  Breastfeeding contributes substantially to overall MTCT of HIV; of children with known timing of infection, as much as 42% of transmission was attributable to breastfeeding. The cumulative probability of transmission increased as the duration of breastfeeding increased (from 1.6% at three months of age to 9.3% at 18 months of age).  </P>
<P>
<U>Characteristics of the mother and infant</U>
</P>
<P>A number of maternal and infant characteristics have been associated with increased risk of breastfeeding transmission of HIV. Maternal factors associated with breastfeeding transmission of HIV include younger maternal age and higher parity (<LINK REF="STD-Miotti-1999" TYPE="STUDY">Miotti 1999</LINK>), recent HIV infection (with concomitantly high viral load) or advanced maternal HIV disease stage, and breast abnormalities. More advanced maternal disease stage, as manifested by low CD4+ cell counts, is a risk factor for late postnatal transmission of HIV (<LINK REF="REF-Semba-1999a" TYPE="REFERENCE">Semba 1999a</LINK>; <LINK REF="STD-Embree-2000" TYPE="STUDY">Embree 2000</LINK>; <LINK REF="REF-Pillay-2000" TYPE="REFERENCE">Pillay 2000</LINK>; <LINK REF="REF-BHITS-2004" TYPE="REFERENCE">BHITS 2004</LINK>) along with higher maternal peripheral blood or human milk viral load (<LINK REF="REF-Semba-1999b" TYPE="REFERENCE">Semba 1999b</LINK>; <LINK REF="REF-Pillay-2000" TYPE="REFERENCE">Pillay 2000</LINK>; <LINK REF="REF-Richardson-2003" TYPE="REFERENCE">Richardson 2003</LINK>). An early case report of the temporal association of HIV acquisition by the child of an HIV-infected woman with a breast abscess suggested that the ingestion of inflammatory cells related to the bacterial infection of the breast contributes to breastfeeding transmission of HIV (<LINK REF="REF-Van-de-Perre-1992" TYPE="REFERENCE">Van de Perre 1992</LINK>). Later studies confirmed the association of transmission of HIV through breastfeeding with maternal breast abnormalities such as breast abscesses, mastitis, and nipple lesions. In Kenya, mastitis and breast abscesses were associated with late postnatal transmission of HIV (<LINK REF="REF-John-2001" TYPE="REFERENCE">John 2001</LINK>). In Malawi, women with increased human milk sodium concentrations consistent with sub-clinical mastitis had higher human milk viral loads than did women without increased human milk sodium concentrations (<LINK REF="REF-Semba-1999a" TYPE="REFERENCE">Semba 1999a</LINK>). In another study in Kenya, maternal nipple lesions and mastitis were each associated with an increased risk of late postnatal transmission (<LINK REF="STD-Embree-2000" TYPE="STUDY">Embree 2000</LINK>).  Oral candidiasis before six months of age is associated with late postnatal transmission (<LINK REF="STD-Embree-2000" TYPE="STUDY">Embree 2000</LINK>), and results of a study in the Ivory Coast suggested maternal breast abscesses and cracked nipples, as well as oral candidiasis in infants, were risk factors for late postnatal transmission of HIV through breastfeeding (<LINK REF="REF-Ekpini-1997" TYPE="REFERENCE">Ekpini 1997</LINK>). Male gender has been associated with breastfeeding transmission of HIV (<LINK REF="REF-BHITS-2004" TYPE="REFERENCE">BHITS 2004</LINK>).</P>
<P>
<U>Characteristics of breast milk</U>
</P>
<P>In addition to higher breast milk viral load (both cell-free and cell-associated), characteristics of breast milk possibly associated with a higher risk of breastfeeding transmission of HIV include the following: lower concentrations of antiviral substances, such as lactoferrin (<LINK REF="REF-Harmsen-1995" TYPE="REFERENCE">Harmsen 1995</LINK>; <LINK REF="REF-Swart-1996" TYPE="REFERENCE">Swart 1996</LINK>), lysozyme, secretory leukocyte protease inhibitor (SLPI) (<LINK REF="REF-Hocini-2000" TYPE="REFERENCE">Hocini 2000</LINK>), and epidermal growth factor (<LINK REF="REF-Donovan-1994" TYPE="REFERENCE">Donovan 1994</LINK>), as well as lesser specific, local immune responses to HIV. Interestingly, HIV-infected women with sub-clinical mastitis, higher human milk viral loads, and higher rates of MTCT had higher human milk concentrations of lysozyme and SLPI than did HIV-infected women without sub-clinical mastitis (<LINK REF="REF-Semba-1999b" TYPE="REFERENCE">Semba 1999b</LINK>). However, SLPI concentrations in human milk have not been found by other investigators to be associated with HIV transmission through breastfeeding (<LINK REF="REF-Becquart-1999" TYPE="REFERENCE">Becquart 1999</LINK>). It has been suggested that epidermal growth factor in colostrum helps to make the gastrointestinal tract less permeable to viral infection (<LINK REF="REF-Donovan-1994" TYPE="REFERENCE">Donovan 1994</LINK>). Higher MTCT of HIV has been associated with lower human milk concentrations of secretory immunoglobulin A and immunoglobulin M during the first several weeks of life in some, (<LINK REF="REF-Van-de-Perre-1993" TYPE="REFERENCE">Van de Perre 1993</LINK>) but not all, studies (<LINK REF="REF-Becquart-2000" TYPE="REFERENCE">Becquart 2000</LINK>).</P>
<P>
<U>Type of infant feeding</U>
</P>
<P>The relationship between infant feeding modality, such as exclusive or mixed feeding, and MTCT of HIV also has been evaluated. In South Africa, data from a randomized clinical trial of vitamin A supplementation to prevent MTCT were re-analyzed to evaluate a possible association between feeding patterns among infants of breastfeeding HIV-infected mothers and MTCT (<LINK REF="REF-Coutsoudis-1999" TYPE="REFERENCE">Coutsoudis 1999</LINK>; <LINK REF="REF-Coutsoudis-2001" TYPE="REFERENCE">Coutsoudis 2001</LINK>). In these analyses, breastfeeding was categorized as exclusive or mixed (i.e., without or with water, other fluids, and food). Women who chose to breastfeed were counseled to consider exclusive breastfeeding. By 15 months of age, children who ever breastfed were more likely to have become HIV-infected than were children who never breastfed.  Of those children who ever breastfed, there was a lower point estimate of transmission for those children who exclusively breastfed until at least three months of age, but no longer than six months of age, as compared to those children with mixed feeding. It has been proposed that feeding of foods other than breast milk in early infancy damages the gastrointestinal tract, with a concomitant increase in the permeability of the gastrointestinal tract to HIV in breast milk (<LINK REF="REF-Catassi-1995" TYPE="REFERENCE">Catassi 1995</LINK>; <LINK REF="REF-Goto-1999" TYPE="REFERENCE">Goto 1999</LINK>).  Iliff and colleagues described similar findings from their study in Zimbabwe (<LINK REF="STD-Iliff-2005" TYPE="STUDY">Iliff 2005</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="2">Description of the intervention, and how the intervention might work  </HEADING>
<P>Because breastfeeding transmission of HIV does occur, and because complete avoidance of breastfeeding is impossible in many settings, identification of risk factors for MTCT of HIV through breastfeeding has been important in order to design interventions to prevent such transmission. There are several potential interventions to prevent breastfeeding transmission of HIV. These include decreasing the duration of exposure to breast milk (e.g., complete avoidance of breastfeeding, early cessation of breastfeeding), decreasing maternal infectivity (e.g., lowering viral load in breast milk through chemical or heat treatment of breast milk, or through ARV prophylaxis to the mother while breastfeeding), addressing factors affecting the transfer of virus from mother-to-child (e.g., mixed feeding, infant thrush, maternal nipple bleeding), and improving infant's defenses against HIV (e.g., through passive or active immunization).   </P>
<P>
<B>Decreasing the duration of exposure to breast milk</B>
</P>
<P>
<U>Complete avoidance of breastfeeding</U>
</P>
<P>Complete avoidance of breastfeeding would be an obvious intervention to prevent HIV transmission through breast milk. However, many issues, including feasibility (clean water), affordability of formula and formula-feeding supplies, cultural acceptability, and the overall nutritional and immunologic status of the child must be considered. </P>
<P>
<U>Early cessation of breastfeeding</U>
</P>
<P>In those circumstances where complete avoidance of breastfeeding is not possible, early cessation from breastfeeding would decrease a child's exposure to breast milk and HIV infection. Again, the issues of feasibility, affordability, cultural acceptability, and nutritional status must be considered. Since the risk of morbidity and mortality associated with replacement feeding was believed to decline after a child's first six months of life, it was considered possible to wean a child off of breast milk and supplement his/her diet with other forms of nutrition after this time (<LINK REF="REF-VanDerslice-1994" TYPE="REFERENCE">VanDerslice 1994</LINK>). However, several studies in sub-Saharan Africa have now demonstrated significant morbidity associated with early cessation (<LINK REF="REF-Kafulafula-2007" TYPE="REFERENCE">Kafulafula 2007</LINK>, <LINK REF="REF-Kourtis-2007" TYPE="REFERENCE">Kourtis 2007</LINK>, <LINK REF="REF-Onyango-2007" TYPE="REFERENCE">Onyango 2007</LINK>, <LINK REF="REF-Thomas-2008" TYPE="REFERENCE">Thomas 2008</LINK>), thus calling for more caution in recommending early cessation of breastfeeding for HIV-infected women in resource-poor settings. Thus, the most recent WHO recommendation states:  &#8220;At six months, if replacement feeding is still not acceptable, feasible, affordable, sustainable and safe, continuation of breastfeeding with additional complementary foods is recommended, while the mother and baby continue to be regularly assessed.  All breastfeeding should stop once a nutritionally adequate and safe diet without breast milk can be provided.&#8221; (<LINK REF="REF-WHO-2006" TYPE="REFERENCE">WHO 2006</LINK>).</P>
<P>
<B>Decreasing maternal infectivity (lowering viral load in breast milk)</B>
</P>
<P>Studies investigating ways to decrease the viral load in breast milk, either through antiretrovirals for HIV-infected mothers while breastfeeding, or through the treatment of breast milk with chemical agents or heat, are also underway.  Preliminary data from observational or non-randomized studies suggest maternal antiretroviral prophylaxis while breastfeeding is associated with a decreased risk of MTCT of HIV (<LINK REF="REF-Arendt-2007" TYPE="REFERENCE">Arendt 2007</LINK>, <LINK REF="REF-Giuliano-2007" TYPE="REFERENCE">Giuliano 2007</LINK>, <LINK REF="STD-Kilewo-2008" TYPE="STUDY">Kilewo 2008</LINK>).  Ongoing randomized clinical trials are exploring the efficacy of different antiretroviral drugs, administered over varying lengths of time to mothers of breastfeeding infants (<LINK REF="REF-Van-der-Horst-2003" TYPE="REFERENCE">Van der Horst 2003</LINK>; <LINK REF="REF-de-Vincenzi-2008" TYPE="REFERENCE">de Vincenzi 2008</LINK>). Other studies are looking at the treatment of human milk, either through chemical agents (<LINK REF="REF-Urdaneta-2005" TYPE="REFERENCE">Urdaneta 2005</LINK>5) or heat (<LINK REF="REF-Israel_x002d_Ballard-2005" TYPE="REFERENCE">Israel-Ballard 2005</LINK>) to inactivate HIV. Limited data suggest heat treatment of breast milk does not have major detrimental effects (<LINK REF="REF-Israel_x002d_Ballard-2008" TYPE="REFERENCE">Israel-Ballard 2008</LINK>) but does lower the viral load in the milk (<LINK REF="REF-Israel_x002d_Ballard-2005" TYPE="REFERENCE">Israel-Ballard 2005</LINK>; <LINK REF="REF-Israel_x002d_Ballard-2007" TYPE="REFERENCE">Israel-Ballard 2007</LINK>).</P>
<P>
<B>Addressing factors affecting the transfer of virus from mother-to-child</B>
</P>
<P>The education and counseling of mothers are also important factors in preventing late postnatal MTCT of HIV.  Having an understanding of proper breastfeeding techniques can help mothers mitigate or quickly treat breast abnormalities associated with HIV transmission. The same holds true for infant candidiasis.  Educating mothers regarding the importance of exclusive breastfeeding in situations where complete avoidance of breastfeeding is not an option appears to be beneficial in terms of initiation and duration of exclusive breastfeeding (<LINK REF="REF-Bland-2008" TYPE="REFERENCE">Bland 2008</LINK>; <LINK REF="REF-Desmond-2008" TYPE="REFERENCE">Desmond 2008</LINK>). </P>
<P>
<B>Improving infants' defenses against HIV infection</B>
</P>
<P>Improving infants' defenses is yet another potential way to prevent MTCT. It has been hypothesized that passive immunization with HIV immune globulin may decrease MTCT, and a randomized clinical trial is underway in Uganda (<LINK REF="REF-Safrit-2004" TYPE="REFERENCE">Safrit 2004</LINK>). Other studies are evaluating the safety and immunogenicity of active HIV vaccines in infants (<LINK REF="REF-Safrit-2004" TYPE="REFERENCE">Safrit 2004</LINK>).   </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Why it is important to do this review  </HEADING>
<P>Major advances have been made in the prevention of MTCT of HIV during the antepartum and intrapartum periods.  However, while MTCT of HIV has become rare in the parts of the world where complete avoidance of breastfeeding is feasible, the epidemic of MTCT of HIV, especially transmission through breastfeeding, continues.  There is an urgent need to develop and implement effective interventions to prevent such transmission. Therefore, this systematic review was undertaken to assess the available evidence regarding interventions to prevent postnatal MTCT of HIV. </P>
<P>
<B>Note (November 2009):</B> Since this review was published in early 2009, several new studies have been published relevant to antiretroviral prophylaxis to prevent HIV transmission during breastfeeding. In light of this new body of evidence, the authors believe that a separate Cochrane review of these interventions is warranted. We anticipate that the new review, titled "Antiretroviral prophylaxis to prevent breast milk transmission of HIV," will be published in Cochrane Library 2010:2. Future updates of the present review will be limited to studies concerned with non-antiretroviral interventions to prevent breast milk transmission of HIV. The authors plan to prepare a substantive update of the present review sometime in 2010.</P>
</SUBSECTION>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-11-07 14:52:46 -0800" MODIFIED_BY="Tara Horvath">
<P>The objectives of this systematic review are to collate and assess the evidence of interventions to decrease late postnatal MTCT of HIV, and to determine the efficacy of such interventions in decreasing late postnatal MTCT of HIV, increasing overall survival, and increasing HIV-free survival.   </P>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-07 14:53:42 -0800" MODIFIED_BY="Tara Horvath">
<SELECTION_CRITERIA MODIFIED="2008-11-07 14:53:23 -0800" MODIFIED_BY="Tara Horvath">
<CRIT_STUDIES MODIFIED="2008-11-07 14:53:13 -0800" MODIFIED_BY="Tara Horvath">
<P>Randomized clinical trials of HIV-infected women and their infants assessing the efficacy of interventions to prevent MTCT of HIV through breast milk were included in the analysis.  Other trials and intervention cohort studies with relevant data also were included, but only in those cases where randomization was not feasible due to the nature of the intervention (i.e., infant feeding modality).  Studies performed in general or specific populations and in hospitals or clinics were included.  Studies performed in any country and published in any language were included.  Studies with historical controls and ecological studies were excluded. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-09-24 12:52:56 -0700" MODIFIED_BY="Tara Horvath">
<P>HIV-infected women, pregnant or postpartum, and their children</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-10-20 13:05:18 -0700" MODIFIED_BY="Tara Horvath">
<P>Interventions to prevent breast milk transmission of HIV, through decreasing the duration of exposure to breast milk, decreasing maternal infectivity, addressing factors affecting the transfer of virus from mother to child, and improving infants&#8217; defenses against HIV infection</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-11-07 14:53:23 -0800" MODIFIED_BY="Tara Horvath">
<P>The outcome measures were the following (among children born to HIV-infected women):</P>
<P>1)     HIV infection;</P>
<P>2)     overall survival; and</P>
<P>3)     HIV-free survival.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-10-30 15:16:30 -0700" MODIFIED_BY="Tara Horvath">
<P>See Cochrane HIV/AIDS Group search strategy.</P>
<P>See <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for our strategies in searching Cochrane CENTRAL, EMBASE and PubMed.</P>
<P>Electronic searches were undertaken using the following databases:  CENTRAL, PubMed, EMBASE, and Gateway and AIDSearch.  Hand searches of the reference lists of all pertinent reviews and studies found also were undertaken, as well as abstracts from relevant conferences, including the International AIDS Conferences and the annual Conference on Retroviruses and Opportunistic Infections.  Experts in the field of HIV prevention were contacted to locate any further studies or relevant conference proceedings not included in the databases to ensure that unpublished studies were included.  The search strategy was iterative. There were no restrictions on language.</P>
<P>With regard to the electronic literature search, the optimal sensitive search strategy developed by The Cochrane Collaboration and detailed in the Cochrane Reviewers&#8217; Handbook (<LINK REF="REF-Handbook-2008" TYPE="REFERENCE">Handbook 2008</LINK>) was used, in conjunction with search terms identified in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>, to identify relevant studies from 1 January 1980 to 15 July 2008.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-11-07 14:53:42 -0800" MODIFIED_BY="Tara Horvath">
<P>The search for studies was performed with the assistance of the Cochrane HIV/AIDS Group.  The authors performed the selection of potentially relevant studies.  The titles, abstracts and descriptor terms of all downloaded material from the electronic searches were read and irrelevant reports discarded to create a pool of potentially eligible studies.  All citations identified then were inspected independently by JSR, TH, and IMI to establish relevance of the article and whether or not the full article should be acquired.  If there was uncertainty, the full article was obtained.     </P>
<SUBSECTION>
<HEADING LEVEL="3">Selection of studies  </HEADING>
<P>JSR, TH, and IMI independently applied the inclusion criteria.  Studies were reviewed for relevance based on study design, types of participants, exposures and outcome measures.  Finally, where resolution was not possible because further information was necessary, attempts were made to contact authors to provide further clarification of data.  The method of conflict resolution was by consensus. </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction and management  </HEADING>
<P>Using a standardized data extraction form, JSR, TH, and IMI independently extracted data.  The following characteristics were extracted from each included study:</P>
<UL>
<LI>Type of intervention</LI>
<LI>Eligibility criteria for enrollment into the study</LI>
<LI>Assessment of risk of bias:  study design, sequence generation, allocation concealment, blinding, loss to follow-up, incomplete outcome data, other potential bias</LI>
<LI>Details regarding the study participants:  sample size, population characteristics, country where study performed, HIV diagnostic testing utilized and ages when testing performed</LI>
<LI>Intervention(s) studied:  non-drug intervention(s), drug intervention(s), comparison groups</LI>
<LI>Outcome measures:  HIV infection status of the child, overall survival, HIV-free survival</LI>
</UL>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-12-03 11:15:15 -0800" MODIFIED_BY="Tara Horvath">
<STUDY_DESCRIPTION MODIFIED="2008-12-03 11:15:15 -0800" MODIFIED_BY="Tara Horvath">
<P>After screening 1349 citations, we identified 17 potentially relevant studies. After reviewing the 17 complete articles for the studies we determined that seven (six randomized clinical trials and one intervention cohort study) met our inclusion criteria (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Only the abstract was available for one additional study (<LINK REF="STD-SIMBA-2003" TYPE="STUDY">SIMBA 2003</LINK>), as this study has never been published. Authors of the study were contacted, but no further information was obtained. Therefore, we were not able to fully consider this study.</P>
<P>Studies included in this review:  <LINK REF="STD-Nduati-2000" TYPE="STUDY">Nduati 2000</LINK>; <LINK REF="STD-Fawzi-2002" TYPE="STUDY">Fawzi 2002</LINK>; <LINK REF="STD-Thior-2006" TYPE="STUDY">Thior 2006</LINK>; <LINK REF="STD-Coovadia-2007" TYPE="STUDY">Coovadia 2007</LINK> <LINK REF="STD-Kuhn-2008" TYPE="STUDY">Kuhn 2008</LINK>; <LINK REF="STD-Kumwenda-2008" TYPE="STUDY">Kumwenda 2008</LINK>; and <LINK REF="STD-SWEN-2008" TYPE="STUDY">SWEN 2008</LINK>. Details of each study are given in the table &#8220;Characteristics of included studies&#8221; and are noted below: </P>
<SUBSECTION>
<HEADING LEVEL="4">Randomized clinical trials</HEADING>
<P>The trial conducted in Kenya by Nduati and colleagues (<LINK REF="STD-Nduati-2000" TYPE="STUDY">Nduati 2000</LINK>), prior to the local availability of interventions to prevent MTCT of HIV, was a randomized clinical trial of breastfeeding versus formula feeding for prevention of MTCT. The primary objective of the trial was to determine the efficacy of complete avoidance of breastfeeding (i.e., formula feeding) in prevention of MTCT of HIV, and to compare overall survival and HIV-free survival in breastfed and formula-fed infants.  HIV-infected women were eligible for inclusion in the trial if they resided in Nairobi and had access to municipal-treated water.  Women were randomized to breastfeed or formula feed at approximately 32 weeks of  gestation.  Of 425 women randomized, 401 were followed to delivery and had live born infants.  Of 401 infants included in the analysis, 94% were followed to HIV infection or mortality endpoints.</P>
<P>Fawzi and colleagues (<LINK REF="STD-Fawzi-2002" TYPE="STUDY">Fawzi 2002</LINK>) conducted a randomized trial of vitamin supplements.  Pregnant women presenting to public antenatal clinics in Dar es Salaam between 12 and 27 weeks of gestation, who resided in and intended to stay in the city until at least one year after delivery, were enrolled.  Participants were randomly assigned in a two-by-two factorial design to receive a daily oral dose of one of four regimens beginning at enrollment and continuing throughout pregnancy and during breastfeeding:  1) vitamin A alone (30 mg beta-carotene plus 5000 IU preformed vitamin A); 2) multivitamins excluding vitamin A (20 mg B1, 20 mg B2, 25 mg B6, 100 mg niacin, 50 micrograms B12, 500 mg vitamin C, 30 mg vitamin E, 0.8 mg folic acid); 3) multivitamins including vitamin A in the same doses as above; and placebo.  At delivery, women in groups 1 and 3 received an additional oral dose of vitamin A (200,000 IU), and women in groups 2 and 4 received placebo. </P>
<P>As part of a clinical trial in Botswana, 1200 HIV-infected women were randomized to breastfeeding with infant zidovudine prophylaxis for six months versus formula feeding plus infant zidovudine for one month to reduce mother-to-child HIV transmission (<LINK REF="STD-Thior-2006" TYPE="STUDY">Thior 2006</LINK>).  Zidovudine 4 mg/kg every 12 hours from birth until one month of age was given to all infants, and discontinued at one month of age in the formula-fed group.  For the breastfed plus zidovudine group, infant zidovudine prophylaxis continued from 1-2  months of age at 4 mg/kg every 8 hours, and from 2-6 months of age (while still breastfeeding) at 6 mg/kg every 8 hours.  All mothers received zidovudine 300 mg orally twice daily from 34 weeks gestation and during labor).  Mothers and infants were randomized to receive single-dose nevirapine or placebo.  Eligibility criteria for the mothers included being between 33-35 weeks gestation, having a positive HIV ELISA on 2 separate samples, being aged 18 years or older, having levels of hemoglobin at 80 g/L or above, absolute neutrophil counts of 1000 or more cells/mm, alanine aminotransferase and aspartate aminotrasferase at 10 or less times the upper limit of normal, and creatinine 1.5 mg/dL (132.6 micromol/L) or less, and not having known intolerance to zidovudine or nevirapine.  The primary efficacy (HIV infection by age 7 months and HIV-free survival by age 18 months) and safety (occurrence of infant adverse events by 7 months of age) end points were evaluated in 1179 infants. </P>
<P>Kuhn et al (<LINK REF="STD-Kuhn-2008" TYPE="STUDY">Kuhn 2008</LINK>) evaluated the effects of early, abrupt cessation of breastfeeding on HIV-free survival of children in Zambia.  HIV-infected women were recruited from antenatal clinics in Lusaka, Zambia that offered HIV counseling and testing, and the two-dose nevirapine regimen for prevention of MTCT of HIV.  Women (at less than 38 weeks of gestation) could volunteer if they intended to breastfeed for any length of time, accepted nevirapine prophylaxis, and agreed to be randomized.  Exclusion criteria were severe pregnancy complications, previous cesarean delivery, and HIV-related conditions requiring hospitalization.  Participants were randomly assigned to one of two groups.  Women assigned to the intervention group were encouraged to breastfeed exclusively to four months, and then to stop breastfeeding abruptly, or as rapidly as possible.  Women assigned in the control group were encouraged to breastfeed exclusively for six months, and then to gradually introduce complementary foods and to continue to breastfeed for as long as they chose.     </P>
<P>A trial of extended infant prophylaxis with nevirapine was conducted in Malawi (<LINK REF="STD-Kumwenda-2008" TYPE="STUDY">Kumwenda 2008</LINK>).  All infants received a single oral dose of nevirapine (2 mg/kg) plus oral zidovudine (4 mg/kd) twice daily for one week.  Drugs for infants in the two extended prophylaxis groups were dispensed beginning at the 1-week study visit.  In Arm 1, the single dose of nevirapine with the one week course of zidovudine was given to the infant (control regimen).  In Arm 2, the control regimen PLUS daily nevirapine (2 mg/kg once daily during week 2, then 4 mg/kg once daily during weeks 3-14) was administered.  In Arm 3, the control regimen PLUS daily nevirapine with zidovudine (4 mg/kg twice daily during weeks 2-5, 4 mg/kg three times daily during weeks 6-8, and 6 mg/kg three times daily during weeks 9-14) was given.  HIV-infected pregnant women were eligible for enrollment into the study, except if the HIV infection was not identified until after they delivered (late presenters).  Other eligibility criteria for the women were:  at least 18 years of age (although women &lt; 18 years of age could be enrolled if they consented and a guardian gave permission), pregnant or had given birth within the previous 24 hours at one of the study clinics, a resident of the study area, willing to return for postnatal follow-up visits for up to 2 years, and intended to breastfeed.  Infants with life-threatening conditions requiring immediate care were excluded.  The women received intrapartum nevirapine prior to the randomization of the infants.   </P>
<P>Three separate but coordinated randomized controlled trials were conducted in Ethiopia, India, and Uganda (<LINK REF="STD-SWEN-2008" TYPE="STUDY">SWEN 2008</LINK>).  Data from these trials were analyzed together.  In Arm 1 (control arm) of the trials, 200 mg nevirapine was provided to women in labor and 2 mg/kg to infants shortly after birth.  In Arm 2 of the trials, this two-dose nevirapine regimen was provided in addition to infant dosing of 5 mg nevirapine each day starting at age 7 days through six weeks of life.  The risk of HIV infection and death at 6 weeks and 6 months of age in infants who were HIV-uninfected at birth was estimated.  The analysis included data for 1887 infants. </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intervention cohort study</HEADING>
<P>A study to assess the risk of HIV transmission and survival associated with exclusive breastfeeding and other types of infant feeding was conducted by Coovadia and colleagues (<LINK REF="STD-Coovadia-2007" TYPE="STUDY">Coovadia 2007</LINK>) in South Africa.  Women were enrolled into a non-randomized intervention cohort study if they were 16 years of age or older, planned to stay in the study area for at least three months after delivery, and provided written informed consent. HIV-infected women and their infants were offered two-dose nevirapine prophylaxis, and a six-month supply of infant formula was offered free at any time in the first 12 months of the infant&#8217;s life.  Antenatal counseling regarding infant feeding options was provided, as were home visits 3-4 times during the first two weeks of life and every two weeks thereafter until the infant was six months old.  Infants who were exclusively  breastfed were compared to those receiving mixed breastfeeding and those receiving replacement feeding. </P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-10-30 17:15:24 -0700" MODIFIED_BY="Tara Horvath">
<P>See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-12-03 11:15:15 -0800" MODIFIED_BY="Tara Horvath">
<P>
<U>Decreasing the duration of exposure to breast milk</U>
</P>
<P>In terms of decreasing the duration of exposure to breast milk, one randomized clinical trial compared MTCT of HIV and mortality among children of HIV-infected women who were breastfed or formula fed (<LINK REF="STD-Nduati-2000" TYPE="STUDY">Nduati 2000</LINK>).  The trial demonstrated the efficacy of complete avoidance of breastfeeding (formula feeding) for the prevention of MTCT of HIV.  The cumulative probability of HIV infection at 24 months was 36.7% (95% CI: 29.4-44.0%) in the breastfeeding arm and 20.5% (95%CI: 14.0-27.0%) in the formula arm (p = 0.001).  Although the 2-year mortality rates in both arms were similar [breastfeeding arm:  24.4% (95%CI: 18.2-30.7%) vs. formula feeding arm: 20.0% (95%CI: 14.4-25.6%); p = 0.30], the rate of HIV-free survival at two years was significantly lower in the breastfeeding arm than in the formula feeding arm (58.0% vs. 70.0%, respectively, p = 0.02).  Another randomized clinical trial evaluated early cessation of breastfeeding (<LINK REF="STD-Kuhn-2008" TYPE="STUDY">Kuhn 2008</LINK>).  Child mortality rates were similar by 24 months in the two groups (23.9% in the intervention group and 24.6% in the control group (p = 0.96)).  There was no significant difference in HIV-free survival at 24 months of age between the two groups according to the intention-to-treat analysis (intervention group:  68.4%, control group:  64.0%; p = 0.13).  Among uninfected children who were still being breastfed at 4 months, there was no significant difference between the groups in HIV-free survival at 24 months (intervention group:  83.9%, control group:  80.7%;  p = 0.27).  Between 4 and 24 months, rates of postnatal HIV transmission were similar (6.2% in the intervention group and 8.8% in the control group, p = 0.19), as was mortality among uninfected children (10.7% in the intervention group and 11.7% in the control group; p = 0.71). </P>
<P>
<U>Decreasing maternal infectivity<BR/>
</U>One clinical trial evaluated micronutrient supplementation for prevention of MTCT of HIV (<LINK REF="STD-Fawzi-2002" TYPE="STUDY">Fawzi 2002</LINK>).  Multivitamins excluding vitamin A had no effect on the overall risk of HIV transmission (RR = 1.04; 95%CI: 0.82-1.32; p = 0.76).  Multivitamins were associated with non-statistically significant reductions in transmission through breastfeeding.  Vitamin A increased the risk of transmission (RR=1.38; 95%CI: 1.09-1.76; p = 0.009).  Multivitamins were associated with non-statistically significant reduction in mortality by 24 months among infants with HIV infection and still alive at 6 weeks. </P>
<P>
<U>Modifying factors affecting the transfer of virus from mother to infant</U>
</P>
<P>One intervention cohort study evaluated the risk of MTCT according to infant feeding modality (<LINK REF="STD-Coovadia-2007" TYPE="STUDY">Coovadia 2007</LINK>).  Of 1276 infants with complete feeding data, breastfed children who also received solids during the first six months of life were significantly more likely to become HIV-infected than were exclusively breastfed children (HR 10.87; 95%CI = 1.51-78.00; p=0.018).  Cumulative 3-month mortality in exclusively breastfed infants was 6.1% (4.74-7.92) vs. 15.1% (7.63-28.73) in infants given replacement feeds (HR 2.06; 1.00-4.27, p=0.051).</P>
<P>
<U>Increasing infant defenses</U>
</P>
<P>Three trials evaluated antiretroviral prophylaxis to the breastfeeding infant for prevention of MTCT of HIV (<LINK REF="STD-Thior-2006" TYPE="STUDY">Thior 2006</LINK>, <LINK REF="STD-Kumwenda-2008" TYPE="STUDY">Kumwenda 2008</LINK>, <LINK REF="STD-SWEN-2008" TYPE="STUDY">SWEN 2008</LINK>). </P>
<P>
<LINK REF="STD-Thior-2006" TYPE="STUDY">Thior 2006</LINK>: Breastfeeding with zidovudine prophylaxis during the first six months of life, with mothers instructed to initiate and complete weaning when the infant was between five and six months of age, was not as efficacious as formula feeding in preventing postnatal HIV transmission; the 7-month HIV infection rates were 5.6% (32 infants in the formula fed group) vs. 9.0% (51 infants in the breastfed plus zidovudine group) (P = 0.04).  Breastfeeding with zidovudine prophylaxis was associated with a lower mortality rate at 7 months, but both strategies had comparable HIV-free survival at 18 months (despite a lower rate of HIV transmission with formula feeding).  Cumulative mortality or HIV infection rates at 18 months were 80 infants (13.9%, formula fed) vs. 86 infants (15.1% breastfed plus zidovudine) (P = 0.60).  Cumulative infant mortality at 7 months was significantly higher for the formula-fed group than for the breastfed plus zidovudine group (9.3% vs. 4.9%; p = 0.003), but this difference diminished beyond month 7 such that the time-to-mortality distributions through age 18 months were not significantly different (P = 0.21). </P>
<P>
<LINK REF="STD-Kumwenda-2008" TYPE="STUDY">Kumwenda 2008</LINK>: Of 3016 infants, 255 were found to have HIV infection.  Among infants who were not infected at birth, the control group had consistently higher rates of HIV infection between the ages of 6 weeks and 18 months, as compared with both extended-prophylaxis groups.  At 9 months, the estimated rate of HIV infection (primary end point) was 10.6% in the control group, 5.2% in the extended nevirapine group (P &lt; 0.001), 6.4% in the extended dual prophylaxis group (P = 0.002).  In this trial, mothers were counseled to breastfeed exclusively for six months and to consider weaning thereafter.  There were no significant differences in terms of transmission between the two extended-prophylaxis groups.  There were no statistically significant differences in mortality by study arm.</P>
<P>HIV-free survival was significantly better through the age of 9 months in both extended prophylaxis groups, and through the age of 15 months in the extended nevirapine group.</P>
<P>
<LINK REF="STD-SWEN-2008" TYPE="STUDY">SWEN 2008</LINK>: At six weeks of age, more children in the control group (one dose of nevirapine) than the extended-dose nevirapine group were infected (relative risk:  0.54; 0.34-0.86; p=0.009).  However, at six months of age, the risk of transmission was similar (relative risk 0.80; 0.58-1.10; p=0.16).  HIV-free survival was higher in the extended prophylaxis arm, at both six weeks (p = 0.008) and six months (p = 0.03). </P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-12-03 11:02:12 -0800" MODIFIED_BY="Tara Horvath">
<SUBSECTION>
<HEADING LEVEL="2">Summary of main results  </HEADING>
<P>Six randomized clinical trials and one intervention cohort study were included in this review.  Complete avoidance of breastfeeding is efficacious in preventing MTCT of HIV.  If breastfeeding is initiated, two interventions are efficacious in preventing transmission:  1) exclusive breastfeeding; and 2) extended antiretroviral prophylaxis. </P>
<P>Specifically, breastfed children who also received solids had higher rates of MTCT of HIV as well as higher three-month mortality rates (compared to exclusive breastfeeding).  With regard to antiretroviral prophylaxis, in a population of HIV-infected women counseled to breastfeed exclusively for six months and to consider weaning thereafter, administration of nevirapine alone or nevirapine with zidovudine until the age of 14 weeks prevents more transmission by 9 months of age than a short-course of antiretrovirals (one dose of nevirapine and one week of zidovudine). HIV-free survival was significantly better through the age of 9 months in both extended prophylaxis groups, and through the age of 15 months in the extended nevirapine group.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-12-03 11:15:15 -0800" MODIFIED_BY="Tara Horvath">
<IMPLICATIONS_PRACTICE MODIFIED="2008-12-03 11:15:15 -0800" MODIFIED_BY="Tara Horvath">
<P>To date, three interventions have been identified for the prevention of late postnatal (breastfeeding) transmission of HIV:  complete avoidance of breastfeeding, exclusive breastfeeding, and antiretroviral prophylaxis to the breastfeeding infant.  Morbidity associated with complete avoidance of breastfeeding (e.g., diarrheal and respiratory disease), in addition to the cost of purchasing formula or other replacement milk and the stigma associated with not breastfeeding, are significant, and in many situations make this intervention infeasible. </P>
<P>Counseling and support for exclusive breastfeeding have increased the proportion of women who pursue this modality of infant feeding.  However, this is time and resource intensive, and will require investment of significant resources in order to have a significant effect in terms of decreasing MTCT of HIV and/or increasing HIV-free survival. </P>
<P>Infant nevirapine prophylaxis for six weeks or 14 weeks (among infants of mothers who were counseled to breastfeed exclusively for six months and to consider weaning thereafter) has shown promise with regard to prevention of MTCT of HIV and for improvement in HIV-free survival.  Such infant antiretroviral prophylaxis was well-tolerated.  However, the implications of the studies to date are that antiretroviral prophylaxis to the breastfeeding infant must continue for the duration of breastfeeding (since the efficacy observed with administration for six or 14 weeks dissipates after prophylaxis is discontinued).  Nevirapine resistance among those infants who fail prophylaxis and become infected while receiving nevirapine (<LINK REF="REF-Arrive-2007" TYPE="REFERENCE">Arrive 2007</LINK>) warrants further evaluation.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-12-03 11:03:22 -0800" MODIFIED_BY="Tara Horvath">
<P>Efficacious interventions for the prevention of late postnatal MTCT of HIV through breastfeeding have been developed, but additional research is needed.  It is important to characterize more completely the mechanism(s) of breast milk transmission of HIV, and to conduct operational research regarding the implementation of efficacious interventions.  Possible limitations of existing interventions (e.g., nevirapine resistance among those infants who fail prophylaxis and become infected while receiving nevirapine) need to be evaluated and understood, the safety profile of available interventions needs to be evaluated further, and new and better interventions developed. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-10-20 13:01:03 -0700" MODIFIED_BY="Tara Horvath">
<P>Valériane Leroy and Francois Dabis, Institut de Santé Publique, Epidémiologie et Développement (ISPED), Bordeaux Cedex, France</P>
<P>Nathan A. Smith, Global Health Sciences, University of California, San Francisco</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None of the authors have any conflict of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-12-10 16:25:50 -0800" MODIFIED_BY="Tara Horvath">
<P>Tara Horvath screened abstracts, selected studies, abstracted data, assessed the risk of bias, reviewed the manuscript, and managed the project. Banyana Madi drafted a related, earlier version of the review, contributed to the protocol of the present review, and reviewed the manuscript.  Irene Iuppa screened abstracts, selected studies, abstracted data, and reviewed the manuscript. Gail Kennedy and George Rutherford also contributed to the protocols design, and reviewed the manuscript. Jennifer Read screened abstracts, selected studies, abstracted data, and wrote most of the manuscript.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-12-10 15:56:28 -0800" MODIFIED_BY="Tara Horvath">
<STUDIES MODIFIED="2008-11-12 15:51:37 -0800" MODIFIED_BY="Tara Horvath">
<INCLUDED_STUDIES MODIFIED="2008-11-12 15:47:15 -0800" MODIFIED_BY="Tara Horvath">
<STUDY DATA_SOURCE="PUB" ID="STD-Coovadia-2007" MODIFIED="2008-10-23 16:59:55 -0700" MODIFIED_BY="Tara Horvath" NAME="Coovadia 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-10-23 16:59:55 -0700" MODIFIED_BY="Tara Horvath" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coovadia HM, Rollins NC, Bland RM, Little K, Coutsoudis A, Bennish ML, et al</AU>
<TI>Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study</TI>
<SO>Lancet</SO>
<YR>2007</YR>
<VL>369</VL>
<NO>9567</NO>
<PG>1107-16</PG>
<IDENTIFIERS MODIFIED="2008-10-23 16:59:53 -0700" MODIFIED_BY="Tara Horvath">
<IDENTIFIER TYPE="PUBMED" VALUE="17398310"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fawzi-2002" MODIFIED="2008-11-12 15:47:15 -0800" MODIFIED_BY="Tara Horvath" NAME="Fawzi 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-11-12 15:47:15 -0800" MODIFIED_BY="Tara Horvath" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fawzi WW, Msamanga GI, Hunter D, Renjifo B, Antelman G, Bang H, et al</AU>
<TI>Randomized trial of vitamin supplements in relation to transmission of HIV-1 through breastfeeding and early child mortality</TI>
<SO>AIDS</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>14</NO>
<PG>1935-44</PG>
<IDENTIFIERS MODIFIED="2008-10-23 16:59:53 -0700" MODIFIED_BY="Tara Horvath">
<IDENTIFIER TYPE="PUBMED" VALUE="12351954"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuhn-2008" MODIFIED="2008-11-07 15:42:31 -0800" MODIFIED_BY="Tara Horvath" NAME="Kuhn 2008" YEAR="2008">
<REFERENCE MODIFIED="2008-11-07 15:42:31 -0800" MODIFIED_BY="Tara Horvath" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuhn L, Aldrovandi GM, Sinkala M, Kankasa C, Semrau K, Mwiya M, et al</AU>
<TI>Effects of early, abrupt weaning on HIV-free survival of children in Zambia</TI>
<SO>N Engl J Med</SO>
<YR>2008</YR>
<VL>359</VL>
<NO>2</NO>
<PG>130-41</PG>
<IDENTIFIERS MODIFIED="2008-10-23 16:59:53 -0700" MODIFIED_BY="Tara Horvath">
<IDENTIFIER TYPE="PUBMED" VALUE="18525036"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kumwenda-2008" MODIFIED="2008-11-07 15:42:43 -0800" MODIFIED_BY="Tara Horvath" NAME="Kumwenda 2008" YEAR="2008">
<REFERENCE MODIFIED="2008-11-07 15:42:43 -0800" MODIFIED_BY="Tara Horvath" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kumwenda NI, Hoover DR, Mofenson LM, Thigpen MC, Kafulafula G, Li Q, et al</AU>
<TI>Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission</TI>
<SO>N Engl J Med</SO>
<YR>2008</YR>
<VL>359</VL>
<NO>2</NO>
<PG>119-29</PG>
<IDENTIFIERS MODIFIED="2008-10-23 16:59:53 -0700" MODIFIED_BY="Tara Horvath">
<IDENTIFIER TYPE="PUBMED" VALUE="18525035"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nduati-2000" MODIFIED="2008-11-07 15:37:00 -0800" MODIFIED_BY="Tara Horvath" NAME="Nduati 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-11-07 15:37:00 -0800" MODIFIED_BY="Tara Horvath" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nduati R, John G, Mbori-Ngacha D, Richardson B, Overbaugh J, Mwatha A, et al</AU>
<TI>Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial</TI>
<SO>JAMA</SO>
<YR>2000</YR>
<VL>283</VL>
<NO>9</NO>
<PG>1167-74</PG>
<IDENTIFIERS MODIFIED="2008-10-23 16:59:53 -0700" MODIFIED_BY="Tara Horvath">
<IDENTIFIER TYPE="PUBMED" VALUE="10703779"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SWEN-2008" MODIFIED="2008-11-07 14:56:55 -0800" MODIFIED_BY="Tara Horvath" NAME="SWEN 2008" YEAR="2008">
<REFERENCE MODIFIED="2008-11-07 14:56:55 -0800" MODIFIED_BY="Tara Horvath" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bedri A, Gudetta B, Isehak A, Kumbi S, Lulseged S, Mengistu Y, et al</AU>
<TI>Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomized controlled trials</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>372</VL>
<NO>9635</NO>
<PG>300-13</PG>
<IDENTIFIERS MODIFIED="2008-10-23 16:59:53 -0700" MODIFIED_BY="Tara Horvath">
<IDENTIFIER TYPE="PUBMED" VALUE="18657709"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thior-2006" MODIFIED="2008-11-07 15:37:15 -0800" MODIFIED_BY="Tara Horvath" NAME="Thior 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-11-07 15:37:15 -0800" MODIFIED_BY="Tara Horvath" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thior I, Lockman S, Smeaton LM, Shapiro RL, Wester C, Heymann SJ, et al</AU>
<TI>Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study</TI>
<SO>JAMA</SO>
<YR>2006</YR>
<VL>296</VL>
<NO>7</NO>
<PG>794-805</PG>
<IDENTIFIERS MODIFIED="2008-10-23 16:59:53 -0700" MODIFIED_BY="Tara Horvath">
<IDENTIFIER TYPE="PUBMED" VALUE="16905785"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-11-12 15:51:37 -0800" MODIFIED_BY="Tara Horvath">
<STUDY DATA_SOURCE="PUB" ID="STD-Becquet-2006" MODIFIED="2008-10-23 16:41:58 -0700" MODIFIED_BY="Tara Horvath" NAME="Becquet 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-10-23 16:41:58 -0700" MODIFIED_BY="Tara Horvath" NOTES="ANRS 1201/1202 Ditrame Plus Study Group" NOTES_MODIFIED="2008-10-23 16:41:58 -0700" NOTES_MODIFIED_BY="Tara Horvath" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Becquet R, Leroy V, Ekouevi DK, Viho I, Castetbon K, Fassinou P, et al</AU>
<TI>Complementary feeding adequacy in relation to nutritional status among early weaned breastfed children who are born to HIV-infected mothers: ANRS 1201/1202 Ditrame Plus, Abidjan, Cote d'Ivoire</TI>
<SO>Pediatrics</SO>
<YR>2006</YR>
<VL>117</VL>
<NO>4</NO>
<PG>e701-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Becquet-2008" MODIFIED="2008-11-07 15:37:26 -0800" MODIFIED_BY="Tara Horvath" NAME="Becquet 2008" YEAR="2008">
<REFERENCE MODIFIED="2008-11-07 15:37:26 -0800" MODIFIED_BY="Tara Horvath" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Becquet R, Ekouevi DK, Menan H, Amani-Bosse C, Bequet L, Viho I, et al</AU>
<TI>Early mixed feeding and breastfeeding beyond 6 months increase the risk of postnatal HIV transmission: ANRS 1201/1202 Ditrame Plus, Abidjan, Cote d'Ivoire</TI>
<SO>Preventive Medicine</SO>
<YR>2008</YR>
<VL>47</VL>
<NO>1</NO>
<PG>27-33</PG>
<IDENTIFIERS MODIFIED="2008-10-29 15:26:38 -0700" MODIFIED_BY="Tara Horvath">
<IDENTIFIER TYPE="PUBMED" VALUE="18190955"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bobat-1997" MODIFIED="2008-11-07 15:37:43 -0800" MODIFIED_BY="Tara Horvath" NAME="Bobat 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-11-07 15:37:43 -0800" MODIFIED_BY="Tara Horvath" NOTES="Journal Article" NOTES_MODIFIED="2008-11-07 15:37:43 -0800" NOTES_MODIFIED_BY="Tara Horvath" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bobat R, Moodley D, Coutsoudis A, Coovadia H</AU>
<TI>Breastfeeding by HIV-1-infected women and outcome in their infants: a cohort study from Durban, South Africa</TI>
<SO>AIDS</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>13</NO>
<PG>1627-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dabis-1999" MODIFIED="2008-10-23 16:41:58 -0700" MODIFIED_BY="Tara Horvath" NAME="Dabis 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-10-23 16:41:58 -0700" MODIFIED_BY="Tara Horvath" NOTES="Clinical Trial" NOTES_MODIFIED="2008-10-23 16:41:58 -0700" NOTES_MODIFIED_BY="Tara Horvath" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dabis F, Msellati P, Meda N, Welffens-Ekra C, You B, Manigart O, et al</AU>
<TI>6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study Group. DIminution de la Transmission Mere-Enfant</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>353</VL>
<NO>9155</NO>
<PG>786-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Embree-2000" MODIFIED="2008-11-07 15:36:03 -0800" MODIFIED_BY="Tara Horvath" NAME="Embree 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-11-07 15:36:03 -0800" MODIFIED_BY="Tara Horvath" NOTES="Journal Article" NOTES_MODIFIED="2008-11-07 15:36:03 -0800" NOTES_MODIFIED_BY="Tara Horvath" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Embree JE, Njenga S, Datta P, Nagelkerke NJ, Ndinya-Achola JO, Mohammed Z, et al</AU>
<TI>Risk factors for postnatal mother-child transmission of HIV-1</TI>
<SO>AIDS</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>16</NO>
<PG>2535-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gray-2005" MODIFIED="2008-11-07 15:37:58 -0800" MODIFIED_BY="Tara Horvath" NAME="Gray 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-11-07 15:37:58 -0800" MODIFIED_BY="Tara Horvath" NOTES="for the PEP Study Group" NOTES_MODIFIED="2008-11-07 15:37:58 -0800" NOTES_MODIFIED_BY="Tara Horvath" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gray GE, Urban M, Chersich MF, Bolton C, van Niekerk R, Violari A, et al</AU>
<TI>A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers</TI>
<SO>AIDS</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>12</NO>
<PG>1289-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guay-1999" MODIFIED="2008-11-07 14:56:55 -0800" MODIFIED_BY="Tara Horvath" NAME="Guay 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-11-07 14:56:55 -0800" MODIFIED_BY="Tara Horvath" NOTES="Using Smart Source Parsing" NOTES_MODIFIED="2008-11-07 14:56:55 -0800" NOTES_MODIFIED_BY="Tara Horvath" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guay LA, Musoke P, Fleming T, et al</AU>
<TI>Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<NO>9181</NO>
<PG>795-802</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iliff-2005" MODIFIED="2008-11-07 15:38:17 -0800" MODIFIED_BY="Tara Horvath" NAME="Iliff 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-11-07 15:38:17 -0800" MODIFIED_BY="Tara Horvath" NOTES="ZVITAMBO study group" NOTES_MODIFIED="2008-11-07 15:38:17 -0800" NOTES_MODIFIED_BY="Tara Horvath" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iliff PJ, Piwoz EG, Tavengwa NV, Zunguza CD, Marinda ET, Nathoo KJ, et al</AU>
<TI>Early exclusive breastfeeding reduces the risk of postnatal HIV-1 transmission and increases HIV-free survival</TI>
<SO>AIDS</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>7</NO>
<PG>699-708</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kilewo-2008" MODIFIED="2008-11-12 15:51:37 -0800" MODIFIED_BY="Tara Horvath" NAME="Kilewo 2008" YEAR="2008">
<REFERENCE MODIFIED="2008-11-12 15:51:37 -0800" MODIFIED_BY="Tara Horvath" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kilewo C, Karlsson K, Massawe A, Lyamuya E, Swai A, Mhalu F, et al</AU>
<TI>Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study</TI>
<SO>J Acquir Immune Defic Syndr</SO>
<YR>2008</YR>
<VL>48</VL>
<NO>3</NO>
<PG>315-23</PG>
<IDENTIFIERS MODIFIED="2008-11-12 15:51:37 -0800" MODIFIED_BY="Tara Horvath">
<IDENTIFIER MODIFIED="2008-11-12 15:51:37 -0800" MODIFIED_BY="Tara Horvath" TYPE="PUBMED" VALUE="18344879"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miotti-1999" MODIFIED="2008-11-07 15:38:38 -0800" MODIFIED_BY="Tara Horvath" NAME="Miotti 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-11-07 15:38:38 -0800" MODIFIED_BY="Tara Horvath" NOTES="Journal Article" NOTES_MODIFIED="2008-11-07 15:38:38 -0800" NOTES_MODIFIED_BY="Tara Horvath" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miotti PG, Taha TE, Kumwenda NI, Broadhead R, Mtimavalye LA, Van der Hoeven L, et al</AU>
<TI>HIV transmission through breastfeeding: a study in Malawi</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>282</VL>
<NO>8</NO>
<PG>744-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SIMBA-2003" MODIFIED="2008-11-12 15:48:28 -0800" MODIFIED_BY="Tara Horvath" NAME="SIMBA 2003" YEAR="Paris, France, 2003.">
<REFERENCE MODIFIED="2008-11-12 15:48:28 -0800" MODIFIED_BY="Tara Horvath" PRIMARY="NO" TYPE="OTHER">
<AU>Vyankandondera J, Luchters S, Hassink E, et al.</AU>
<TI>Reducing risk of HIV-1 transmission from mother to infant through breastfeeding using antiretroviral prophylaxis in infants (SIMBA study) [abstract # LB7]</TI>
<SO>Paper presented at: the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment;</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-12-10 15:56:28 -0800" MODIFIED_BY="Tara Horvath">
<ADDITIONAL_REFERENCES MODIFIED="2008-12-10 15:56:28 -0800" MODIFIED_BY="Tara Horvath">
<REFERENCE ID="REF-AAP-1995" MODIFIED="2008-10-28 16:02:11 -0700" MODIFIED_BY="Tara Horvath" NAME="AAP 1995" TYPE="JOURNAL_ARTICLE">
<AU>American Academy of Pediatrics, Committee on Pediatric AIDS</AU>
<TI>Human milk, breastfeeding, and transmission of human immunodeficiency virus in the United States</TI>
<SO>Pediatrics</SO>
<YR>1995</YR>
<VL>96 977 &#8211;979</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arendt-2007" MODIFIED="2008-11-12 15:38:36 -0800" MODIFIED_BY="Tara Horvath" NAME="Arendt 2007" TYPE="OTHER">
<AU>Arendt V, Ndimubanzi P, Ndayabisa G, Muganda J, Courteille O, Rudanga C, et al</AU>
<TI>AMATA Study: effectiveness of antiretroviral therapy in breastfeeding mothers to prevent post-natal vertical transmission in Rwanda [Abstract TuAX102]</TI>
<SO>Paper presented at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention,</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arrive-2007" MODIFIED="2008-11-12 15:34:35 -0800" MODIFIED_BY="Tara Horvath" NAME="Arrive 2007" TYPE="JOURNAL_ARTICLE">
<AU>Arrivé E, Newell ML, Ekouevi DK, Chaix ML, Thiebaut R, Masquelier B, et al</AU>
<TI>Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis</TI>
<SO>Int J Epidemiol</SO>
<YR>2007 Oct</YR>
<VL>36</VL>
<NO>5</NO>
<PG>1009-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Becquart-1999" MODIFIED="2008-11-12 15:40:33 -0800" MODIFIED_BY="Tara Horvath" NAME="Becquart 1999" TYPE="JOURNAL_ARTICLE">
<AU>Becquart P, Gressenguet G, Hocini H, Kazatchkine MD, Belec L</AU>
<TI>Secretory leukocyte protease inhibitor in colostrum and breast milk is not a major determinant of the protection of early postnatal transmission of HIV</TI>
<SO>AIDS</SO>
<YR>1999</YR>
<VL>13 2599&#8211;2602</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Becquart-2000" MODIFIED="2008-11-12 15:48:54 -0800" MODIFIED_BY="Tara Horvath" NAME="Becquart 2000" TYPE="JOURNAL_ARTICLE">
<AU>Becquart P, Hocini H, Levy M, Sepou A, Kazatchkine MD, Belec L</AU>
<TI>Secretory anti-human immunodeficiency virus (HIV) antibodies in colostrum and breast milk are not a major determinant of the protection of early postnatal transmission of HIV</TI>
<SO>J Infect Dis</SO>
<YR>2000</YR>
<VL>181 532 &#8211;539</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BHITS-2004" MODIFIED="2008-10-23 17:01:06 -0700" MODIFIED_BY="Tara Horvath" NAME="BHITS 2004" TYPE="JOURNAL_ARTICLE">
<AU>Breastfeeding and HIV International Transmission Study Group.</AU>
<TI>Late postnatal transmission of HIV-1 in breast-fed children: An individual patient data meta-analysis</TI>
<SO>J Infect Dis</SO>
<YR>2004</YR>
<VL>189</VL>
<PG>2154-2166</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-2008" MODIFIED="2008-10-28 16:03:22 -0700" MODIFIED_BY="Tara Horvath" NAME="Bland 2008" TYPE="JOURNAL_ARTICLE">
<AU>Bland RM, Little KE, Coovadia HM, Coutsoudis A, Rollins NC, Newell ML</AU>
<TI>Intervention to promote exclusive breast-feeding for the first 6 months of life in a high HIV prevalence area</TI>
<SO>AIDS</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>7</NO>
<PG>883-91</PG>
<IDENTIFIERS MODIFIED="2008-10-23 17:22:56 -0700" MODIFIED_BY="Tara Horvath">
<IDENTIFIER TYPE="PUBMED" VALUE="18427207"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bond-2007" MODIFIED="2008-10-23 17:01:10 -0700" MODIFIED_BY="Tara Horvath" NAME="Bond 2007" TYPE="JOURNAL_ARTICLE">
<AU>Bond K, Horváth T, Harvey K, Wiysonge CS, Read JS.</AU>
<TI>The Cochrane Library and mother-to-child transmission of HIV: an umbrella review</TI>
<SO>Evidence-Based Child Health: A Cochrane Review Journal</SO>
<YR>2007</YR>
<VL>2</VL>
<NO>1</NO>
<PG>4-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Catassi-1995" MODIFIED="2008-11-12 15:31:40 -0800" MODIFIED_BY="Tara Horvath" NAME="Catassi 1995" TYPE="JOURNAL_ARTICLE">
<AU>Catassi C, Bonucci A, Coppa GV, Carlucci A, Giorgi PL</AU>
<TI>Intestinal permeability changes during the first month: effect of natural versus artificial feeding</TI>
<SO>J Pediatr Gastroenterol Nutr</SO>
<YR>1995 Nov</YR>
<VL>21</VL>
<NO>4</NO>
<PG>383-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cesar-1999" MODIFIED="2008-10-28 16:03:45 -0700" MODIFIED_BY="Tara Horvath" NAME="Cesar 1999" TYPE="JOURNAL_ARTICLE">
<AU>Cesar JA, Victora CG, Barros FC, Santos IS, Flores JA</AU>
<TI>Impact of breast feeding on admission for pneumonia during postneonatal period in Brazil nested case-control study</TI>
<SO>BMJ</SO>
<YR>1999</YR>
<VL>318 1316 &#8211;1320</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coovadia-2007" MODIFIED="2008-10-23 17:01:22 -0700" MODIFIED_BY="Tara Horvath" NAME="Coovadia 2007" TYPE="JOURNAL_ARTICLE">
<AU>Coovadia HM, Rollins NC, Bland RM, Little K, Coutsoudis A, Bennish ML, Newell ML</AU>
<TI>Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study</TI>
<SO>Lancet</SO>
<YR>2007</YR>
<VL>369</VL>
<PG>1107-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coutsoudis-1999" MODIFIED="2008-11-12 15:41:06 -0800" MODIFIED_BY="Tara Horvath" NAME="Coutsoudis 1999" TYPE="JOURNAL_ARTICLE">
<AU>Coutsoudis A, Pillay K, Spooner E, Kuhn L, Coovadia HM</AU>
<TI>Influence of infant-feeding patterns on early mother-to-child transmission of HIV in Durban, South Africa a prospective cohort study. South African Vitamin A Study Group</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354 471 &#8211;476</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coutsoudis-2001" MODIFIED="2008-11-12 15:41:14 -0800" MODIFIED_BY="Tara Horvath" NAME="Coutsoudis 2001" TYPE="JOURNAL_ARTICLE">
<AU>Coutsoudis A, Pillay K, Kuhn L, Spooner E, Tsai WY, Coovadia HM</AU>
<TI>Method of feeding and transmission of HIV from mothers to children by 15 months of age prospective cohort study from Durban, South Africa. South African Vitamin A Study Group</TI>
<SO>AIDS</SO>
<YR>2001</YR>
<VL>15 379 &#8211;387</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Vincenzi-2008" MODIFIED="2008-11-12 15:43:01 -0800" MODIFIED_BY="Tara Horvath" NAME="de Vincenzi 2008" TYPE="OTHER">
<AU>de Vincenzi I and the Kesho Bora Study Group</AU>
<TI>HIV-free survival at 12 months among children born to HIV-infected women receiving antiretrovirals from 34-36 weeks of pregnancy [abstract # 638]</TI>
<SO>Paper presented at the15th Conference on Retroviruses and Opportunistic Infections (CROI),</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Desmond-2008" MODIFIED="2008-11-12 15:41:36 -0800" MODIFIED_BY="Tara Horvath" NAME="Desmond 2008" TYPE="JOURNAL_ARTICLE">
<AU>Desmond C, Bland RM, Boyce G, Coovadia HM, Coutsoudis A, Rollins N, et al</AU>
<TI>Scaling-up exclusive breastfeeding support programmes: the example of KwaZulu-Natal</TI>
<SO>PLoS ONE</SO>
<YR>2008</YR>
<VL>3</VL>
<NO>6</NO>
<PG>e2454</PG>
<IDENTIFIERS MODIFIED="2008-11-12 15:41:36 -0800" MODIFIED_BY="Tara Horvath">
<IDENTIFIER MODIFIED="2008-11-12 15:41:36 -0800" MODIFIED_BY="Tara Horvath" TYPE="PUBMED" VALUE="18560596"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Donovan-1994" MODIFIED="2008-10-28 16:04:36 -0700" MODIFIED_BY="Tara Horvath" NAME="Donovan 1994" TYPE="JOURNAL_ARTICLE">
<AU>Donovan SM, Odle J</AU>
<TI>Growth factors in milk as mediators of infant development</TI>
<SO>Annu Rev Nutr</SO>
<YR>1994</YR>
<VL>14 147 &#8211;167</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ekpini-1997" MODIFIED="2008-11-12 15:43:15 -0800" MODIFIED_BY="Tara Horvath" NAME="Ekpini 1997" TYPE="JOURNAL_ARTICLE">
<AU>Ekpini ER, Wiktor SZ, Satten GA, et al</AU>
<TI>Late postnatal mother-to-child transmission of HIV in Abidjan, Côte d&#8217;Ivoire</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349 1054 &#8211;1059</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Embree-2000" MODIFIED="2008-10-28 16:05:17 -0700" MODIFIED_BY="Tara Horvath" NAME="Embree 2000" TYPE="JOURNAL_ARTICLE">
<AU>Embree JE, Njenga S, Datta P, et al</AU>
<TI>Risk factors for postnatal mother-child transmission of HIV</TI>
<SO>AIDS</SO>
<YR>2000</YR>
<VL>14</VL>
<PG>2535 &#8211;2541</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fawzi-1998" MODIFIED="2008-10-29 12:56:14 -0700" MODIFIED_BY="Tara Horvath" NAME="Fawzi 1998" TYPE="JOURNAL_ARTICLE">
<AU>Fawzi WW, Msamanga GI, Spiegelman D, Urassa EJ, McGrath N, Mwakagile D, et al</AU>
<TI>Randomised trial of effects of vitamin supplements on pregnancy outcomes and T cell counts in HIV-1-infected women in Tanzania</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>351</VL>
<NO>9114</NO>
<PG>1477-82</PG>
<IDENTIFIERS MODIFIED="2008-10-29 12:56:12 -0700" MODIFIED_BY="Tara Horvath">
<IDENTIFIER TYPE="PUBMED" VALUE="9605804"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fawzi-1999" MODIFIED="2008-11-07 15:40:21 -0800" MODIFIED_BY="Tara Horvath" NAME="Fawzi 1999" TYPE="JOURNAL_ARTICLE">
<AU>Fawzi WW, Msamanga GI, Spiegelman D, Urassa EJ, Hunter DJ</AU>
<TI>Rationale and design of the Tanzania Vitamin and HIV Infection Trial</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1999</YR>
<VL>20</VL>
<NO>1</NO>
<PG>75-90</PG>
<IDENTIFIERS MODIFIED="2008-10-28 15:51:37 -0700" MODIFIED_BY="Tara Horvath">
<IDENTIFIER TYPE="PUBMED" VALUE="10027501"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fawzi-2000" MODIFIED="2008-11-12 15:53:09 -0800" MODIFIED_BY="Tara Horvath" NAME="Fawzi 2000" TYPE="JOURNAL_ARTICLE">
<AU>Fawzi WW, Msamanga G, Hunter D, Urassa E, Renjifo B, Mwakagile D, et al</AU>
<TI>Randomized trial of vitamin supplements in relation to vertical transmission of HIV-1 in Tanzania</TI>
<SO>J Acquir Immune Defic Syndr</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>3</NO>
<PG>246-54</PG>
<IDENTIFIERS MODIFIED="2008-10-28 15:51:37 -0700" MODIFIED_BY="Tara Horvath">
<IDENTIFIER TYPE="PUBMED" VALUE="10839660"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Giuliano-2007" MODIFIED="2008-11-12 16:07:57 -0800" MODIFIED_BY="Tara Horvath" NAME="Giuliano 2007" TYPE="JOURNAL_ARTICLE">
<AU>Giuliano M, Guidotti G, Andreotti M, Pirillo MF, Villani P, Liotta G, et al</AU>
<TI>Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load: a study within the Drug Resource Enhancement Against AIDS and Malnutrition Program</TI>
<SO>J Acquir Immune Defic Syndr</SO>
<YR>2007</YR>
<VL>44</VL>
<NO>3</NO>
<PG>286-91</PG>
<IDENTIFIERS MODIFIED="2008-10-23 17:22:56 -0700" MODIFIED_BY="Tara Horvath">
<IDENTIFIER TYPE="PUBMED" VALUE="17146372"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Goto-1999" MODIFIED="2008-11-12 16:24:57 -0800" MODIFIED_BY="Tara Horvath" NAME="Goto 1999" TYPE="JOURNAL_ARTICLE">
<AU>Goto K, Chew F, Torún B, Peerson JM, Brown KH</AU>
<TI>Epidemiology of altered intestinal permeability to lactulose and mannitol in Guatemalan infants</TI>
<SO>Pediatr Gastroenterol Nutr</SO>
<YR>1999 Mar;28</YR>
<VL>3</VL>
<PG>282-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Handbook-2008" MODIFIED="2008-11-12 17:36:37 -0800" MODIFIED_BY="Tara Horvath" NAME="Handbook 2008" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<PB>Wiley-Blackwell</PB>
<CY>Chichester (UK)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harmsen-1995" MODIFIED="2008-10-28 16:07:18 -0700" MODIFIED_BY="Tara Horvath" NAME="Harmsen 1995" TYPE="JOURNAL_ARTICLE">
<AU>Harmsen MC, Swart RJ, de Bethune MP, et al</AU>
<TI>Antiviral effects of plasma and milk proteins lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro</TI>
<SO>J Infect Dis</SO>
<YR>1995</YR>
<VL>172 380 &#8211;388</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hocini-2000" MODIFIED="2008-10-28 16:07:54 -0700" MODIFIED_BY="Tara Horvath" NAME="Hocini 2000" TYPE="JOURNAL_ARTICLE">
<AU>Hocini H, Becquart P, Bouhlal H, Adle-Biassette H, Kazatchkine MD, Belec L</AU>
<TI>Secretory leukocyte protease inhibitor inhibits infection of monocytes and lymphocytes with human immunodeficiency virus type 1 but does not interfere with transcytosis of cell-associated virus across tight epithelial barriers</TI>
<SO>Clin Diagn Lab Immunol</SO>
<YR>2000</YR>
<VL>7</VL>
<PG>515 &#8211;518</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Israel_x002d_Ballard-2005" MODIFIED="2008-11-12 16:08:11 -0800" MODIFIED_BY="Tara Horvath" NAME="Israel-Ballard 2005" TYPE="JOURNAL_ARTICLE">
<AU>Israel-Ballard K, Chantry C, Dewey K, Lonnerdal B, Sheppard H, Donovan R, et al</AU>
<TI>Viral, nutritional, and bacterial safety of flash-heated and pretoria-pasteurized breast milk to prevent mother-to-child transmission of HIV in resource-poor countries: a pilot study</TI>
<SO>J Acquir Immune Defic Syndr</SO>
<YR>2005</YR>
<VL>40</VL>
<NO>2</NO>
<PG>175-81</PG>
<IDENTIFIERS MODIFIED="2008-10-23 17:22:56 -0700" MODIFIED_BY="Tara Horvath">
<IDENTIFIER TYPE="PUBMED" VALUE="16186735"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Israel_x002d_Ballard-2007" MODIFIED="2008-11-12 16:08:30 -0800" MODIFIED_BY="Tara Horvath" NAME="Israel-Ballard 2007" TYPE="JOURNAL_ARTICLE">
<AU>Israel-Ballard K, Donovan R, Chantry C, Coutsoudis A, Sheppard H, Sibeko L, et al</AU>
<TI>Flash-heat inactivation of HIV-1 in human milk: a potential method to reduce postnatal transmission in developing countries</TI>
<SO>J Acquir Immune Defic Syndr</SO>
<YR>2007</YR>
<VL>45</VL>
<NO>3</NO>
<PG>318-23</PG>
<IDENTIFIERS MODIFIED="2008-10-23 17:22:56 -0700" MODIFIED_BY="Tara Horvath">
<IDENTIFIER TYPE="PUBMED" VALUE="17514015"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Israel_x002d_Ballard-2008" MODIFIED="2008-11-12 16:08:44 -0800" MODIFIED_BY="Tara Horvath" NAME="Israel-Ballard 2008" TYPE="JOURNAL_ARTICLE">
<AU>Israel-Ballard KA, Abrams BF, Coutsoudis A, Sibeko LN, Cheryk LA, Chantry CJ</AU>
<TI>Vitamin content of breast milk from HIV-1-infected mothers before and after flash-heat treatment</TI>
<SO>J Acquir Immune Defic Syndr</SO>
<YR>2008</YR>
<VL>48</VL>
<NO>4</NO>
<PG>444-9</PG>
<IDENTIFIERS MODIFIED="2008-10-23 17:22:56 -0700" MODIFIED_BY="Tara Horvath">
<IDENTIFIER TYPE="PUBMED" VALUE="18614920"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-John-2001" MODIFIED="2008-10-23 17:01:58 -0700" MODIFIED_BY="Tara Horvath" NAME="John 2001" TYPE="JOURNAL_ARTICLE">
<AU>John GC, Richardson BA, Nduati RW, Mbori-Ngacha D, Kreiss JK</AU>
<TI>Timing of breast milk HIV transmission a meta-analysis. East Afr Med J</TI>
<YR>2001</YR>
<VL>78 75 &#8211;79</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kafulafula-2007" MODIFIED="2008-11-12 15:46:24 -0800" MODIFIED_BY="Tara Horvath" NAME="Kafulafula 2007" TYPE="OTHER">
<AU>Kafulafula G, Thigpen M, Hoover D et al</AU>
<TI>Post-weaning gastroenteritis and mortality in HIV-uninfected African infants receiving antiretroviral prophylaxis to prevent MTCT of HIV-1 [abstract # 773]</TI>
<SO>Paper presented at the 14th Conference on Retroviruses and Opportunistic Infections (CROI),</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kourtis-2007" MODIFIED="2008-11-12 16:09:52 -0800" MODIFIED_BY="Tara Horvath" NAME="Kourtis 2007" TYPE="OTHER">
<AU>Kourtis A. et al</AU>
<TI>Diarrhea in Uninfected Infants of HIV-infected Mothers Who Stop Breastfeeding at 6 Months: The BAN Study Experience [abstract #772]</TI>
<SO>Paper presented at presented at the 14th Conference on Retroviruses and Opportunistic Infections (CROI),</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kramer-2001" MODIFIED="2008-11-07 14:56:55 -0800" MODIFIED_BY="Tara Horvath" NAME="Kramer 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kramer MS, Chalmers B, Hodnett ED, et al</AU>
<TI>Promotion of Breastfeeding Intervention Trial (PROBIT) a randomized trial in the Republic of Belarus. JAMA</TI>
<YR>2001</YR>
<VL>285 413 &#8211;420</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kumwenda-2008-Supplement" MODIFIED="2008-11-07 15:41:56 -0800" MODIFIED_BY="Tara Horvath" NAME="Kumwenda 2008 Supplement" TYPE="OTHER">
<TI>Supplement to: Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reducebreast-milk HIV-1 transmission.</TI>
<SO>N Engl J Med</SO>
<YR>2008</YR>
<VL>359</VL>
<PG>119-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lindegren-1999" MODIFIED="2008-10-23 17:02:10 -0700" MODIFIED_BY="Tara Horvath" NAME="Lindegren 1999" TYPE="JOURNAL_ARTICLE">
<AU>Lindegren ML, Byers RH Jr, Thomas P, et al</AU>
<TI>Trends in perinatal transmission of HIVAIDS in the United States. JAMA</TI>
<YR>1999</YR>
<VL>282 531 &#8211;538</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mbori_x002d_Ngacha-2001" MODIFIED="2008-11-07 15:43:21 -0800" MODIFIED_BY="Tara Horvath" NAME="Mbori-Ngacha 2001" TYPE="JOURNAL_ARTICLE">
<AU>Mbori-Ngacha D, Nduati R, John G, Reilly M, Richardson B, Mwatha A, et al</AU>
<TI>Morbidity and mortality in breastfed and formula-fed infants of HIV-1-infected women: A randomized clinical trial</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>286</VL>
<NO>19</NO>
<PG>2413-20</PG>
<IDENTIFIERS MODIFIED="2008-10-28 15:57:46 -0700" MODIFIED_BY="Tara Horvath">
<IDENTIFIER TYPE="PUBMED" VALUE="11712936"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Miotti-1999" MODIFIED="2008-10-23 17:02:12 -0700" MODIFIED_BY="Tara Horvath" NAME="Miotti 1999" TYPE="JOURNAL_ARTICLE">
<AU>Miotti PG, Taha TE, Kumwenda NI, et al</AU>
<TI>HIV transmission through breastfeeding a study in Malawi. JAMA</TI>
<YR>1999; 282</YR>
<VL>744 &#8211;749</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MMWR-1985" MODIFIED="2008-10-23 17:02:14 -0700" MODIFIED_BY="Tara Horvath" NAME="MMWR 1985" TYPE="OTHER">
<AU>Centers for Disease Control and Prevention</AU>
<TI>Recommendations for assisting in the prevention of perinatal transmission of human T-lymphotropic virus type IIIlymphadenopathy-associated virus and acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep</TI>
<YR>1985</YR>
<VL>34 721 &#8211;726, 731&#8211;732</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Newell-2004" MODIFIED="2008-10-23 17:02:16 -0700" MODIFIED_BY="Tara Horvath" NAME="Newell 2004" TYPE="JOURNAL_ARTICLE">
<AU>Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F; Ghent International AIDS Society (IAS) Working Group on HIV Infection in Women and Children.</AU>
<TI>Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet</TI>
<YR>2004 Oct 2-8</YR>
<VL>364</VL>
<NO>9441</NO>
<PG>1236-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Onyango-2007" MODIFIED="2008-11-12 16:10:59 -0800" MODIFIED_BY="Tara Horvath" NAME="Onyango 2007" TYPE="OTHER">
<AU>Onyango C et al.</AU>
<TI>Early Breastfeeding Cessation among HIV-exposed Negative Infants and Risk of Serious Gastroenteritis: Findings from a Perinatal Prevention Trial in Kampala, Uganda [abstract # 775]</TI>
<SO>Paper presented at the 14th Conference on Retroviruses and Opportunistic Infections (CROI)</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pebley-1986" MODIFIED="2008-10-23 17:02:22 -0700" MODIFIED_BY="Tara Horvath" NAME="Pebley 1986" TYPE="JOURNAL_ARTICLE">
<AU>Pebley AR, Millman S</AU>
<TI>Birthspacing and child survival. Int Fam Plann Perspect</TI>
<YR>1986</YR>
<VL>12 71 &#8211;79</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pillay-2000" MODIFIED="2008-10-23 17:02:28 -0700" MODIFIED_BY="Tara Horvath" NAME="Pillay 2000" TYPE="JOURNAL_ARTICLE">
<AU>Pillay K, Coutsoudis A, York D, Kuhn L, Coovadia HM</AU>
<TI>Cell-free virus in breast milk of HIV -seropositive women. J Acquir Immune Defic Syndr</TI>
<YR>2000</YR>
<VL>24 330 &#8211;336</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rankin-2005" MODIFIED="2008-11-12 14:19:55 -0800" MODIFIED_BY="Tara Horvath" NAME="Rankin 2005" TYPE="JOURNAL_ARTICLE">
<AU>Rankin W, Brennan S, Schell E, et al</AU>
<TI>The Stigma of Being HIV-Positive in Africa</TI>
<SO>PLoS Medicine</SO>
<YR>August 2005</YR>
<VL>2</VL>
<NO>8</NO>
<PG>247-249</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Read-1999" MODIFIED="2008-10-23 17:02:29 -0700" MODIFIED_BY="Tara Horvath" NAME="Read 1999" TYPE="JOURNAL_ARTICLE">
<AU>Read JS</AU>
<TI>Preventing mother-to-child transmission of HIV the USA experience. Prenat Neonatal Med</TI>
<YR>1999</YR>
<VL>4 391 &#8211;397</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Read-2003" MODIFIED="2008-10-23 17:02:31 -0700" MODIFIED_BY="Tara Horvath" NAME="Read 2003" TYPE="JOURNAL_ARTICLE">
<AU>Read JS</AU>
<TI>American Academy of Pediatrics Committee on Pediatric AIDS. Human milk, breastfeeding, and transmission of human immunodeficiency virus type 1 in the United States</TI>
<SO>Pediatrics</SO>
<YR>2003; 112</YR>
<VL>1196-1205</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Read-2005a" MODIFIED="2008-09-24 13:33:58 -0700" MODIFIED_BY="Tara Horvath" NAME="Read 2005a" TYPE="BOOK_SECTION">
<AU>Read JS</AU>
<TI>Prevention of mother-to-child transmission of HIV</TI>
<SO>Textbook of Pediatric HIV Care</SO>
<YR>2005</YR>
<ED>Zeichner SL, Read JS</ED>
<PB>Cambridge University Press</PB>
<CY>Cambridge, England</CY>
<IDENTIFIERS MODIFIED="2008-09-24 13:33:58 -0700" MODIFIED_BY="Tara Horvath"/>
</REFERENCE>
<REFERENCE ID="REF-Read-2005b" MODIFIED="2008-10-24 16:35:20 -0700" MODIFIED_BY="Tara Horvath" NAME="Read 2005b" TYPE="JOURNAL_ARTICLE">
<AU>Read JS, Newell ML</AU>
<TI>Cesarean section for preventing mother-to-child transmission of HIV infection</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<VL>4</VL>
<IDENTIFIERS MODIFIED="2008-09-24 13:33:47 -0700" MODIFIED_BY="Tara Horvath"/>
</REFERENCE>
<REFERENCE ID="REF-Richardson-2003" MODIFIED="2008-10-23 17:02:36 -0700" MODIFIED_BY="Tara Horvath" NAME="Richardson 2003" TYPE="JOURNAL_ARTICLE">
<AU>Richardson BA, John-Steward GC, Hughes JP, et al</AU>
<TI>Breast-milk infectivity in human immunodeficiency virus type 1-infected mothers. J Infect Dis</TI>
<YR>2003</YR>
<VL>187 736 &#8211;740</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Safrit-2004" MODIFIED="2008-11-12 15:10:21 -0800" MODIFIED_BY="Tara Horvath" NAME="Safrit 2004" TYPE="JOURNAL_ARTICLE">
<AU>Safrit JT, Ruprecht R, Ferrantelli F, Xu W, Kitabwalla M, Van Rompay K, et al</AU>
<TI>Immunoprophylaxis to prevent mother-to-child transmission of HIV-1</TI>
<SO>J Acquir Immune Defic Syndr</SO>
<YR>2004 Feb 1</YR>
<VL>35</VL>
<NO>2</NO>
<PG>169-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Semba-1999a" MODIFIED="2008-10-23 17:02:39 -0700" MODIFIED_BY="Tara Horvath" NAME="Semba 1999a" TYPE="JOURNAL_ARTICLE">
<AU>Semba RD, Kumwenda N, Hoover DR, et al.</AU>
<TI>Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1</TI>
<SO>J Infect Dis</SO>
<YR>1999</YR>
<VL>180</VL>
<PG>93-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Semba-1999b" MODIFIED="2008-11-12 14:22:39 -0800" MODIFIED_BY="Tara Horvath" NAME="Semba 1999b" TYPE="JOURNAL_ARTICLE">
<AU>Semba RD, Kumwenda N, Taha TE, et al</AU>
<TI>Mastitis and immunological factors in breast milk of human immunodeficiency virus-infected women.</TI>
<SO>J Hum Lact</SO>
<YR>1999</YR>
<VL>15 301 &#8211;306</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Swart-1996" MODIFIED="2008-10-23 17:02:48 -0700" MODIFIED_BY="Tara Horvath" NAME="Swart 1996" TYPE="JOURNAL_ARTICLE">
<AU>Swart PJ, Kuipers ME, Smit C, et al</AU>
<TI>Antiviral effects of milk proteins acylation results in polyanionic compounds with potent activity against human immunodeficiency virus types 1 and 2 in vitro. AIDS Res Hum Retroviruses</TI>
<YR>1996</YR>
<VL>12 769 &#8211;775</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thapa-1988" MODIFIED="2008-10-23 17:02:52 -0700" MODIFIED_BY="Tara Horvath" NAME="Thapa 1988" TYPE="JOURNAL_ARTICLE">
<AU>Thapa S, Short RV, Potts M</AU>
<TI>Breast feeding, birth spacing and their effects on child survival. Nature</TI>
<YR>1988</YR>
<VL>335 679 &#8211;682</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thomas-2008" MODIFIED="2008-11-12 15:46:46 -0800" MODIFIED_BY="Tara Horvath" NAME="Thomas 2008" TYPE="OTHER">
<AU>Thomas T et al</AU>
<TI>Rates of diarrhea associated with early weaning among infants in Kisumu, Kenya [abstract # 774]</TI>
<SO>Paper presented at the 15th Conference on Retroviruses and Opportunistic Infections (CROI)</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-UNAIDS-2008" MODIFIED="2008-09-24 13:43:23 -0700" MODIFIED_BY="Tara Horvath" NAME="UNAIDS 2008" TYPE="OTHER">
<AU>Joint United Nations Programme on HIV/AIDS</AU>
<TI>2007 AIDS Epidemic Update</TI>
<YR>Geneva: 2008</YR>
<CY>Geneva</CY>
<MD>A</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Urdaneta-2005" MODIFIED="2008-11-12 15:07:03 -0800" MODIFIED_BY="Tara Horvath" NAME="Urdaneta 2005" TYPE="JOURNAL_ARTICLE">
<AU>Urdaneta S, Wigdahl B, Neely EB, Berlin CM Jr, Schengrund CL, Lin HM, Howett MK</AU>
<TI>Inactivation of HIV-1 in breast milk by treatment with the alkyl sulfate microbicide sodium dodecyl sulfate (SDS)</TI>
<SO>Retrovirology</SO>
<YR>2005 Apr 29</YR>
<VL>2</VL>
<NO>28</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-de-Perre-1992" MODIFIED="2008-11-12 15:50:15 -0800" MODIFIED_BY="Tara Horvath" NAME="Van de Perre 1992" TYPE="JOURNAL_ARTICLE">
<AU>Van de Perre P, Hitimana DG, Simonon A, et al</AU>
<TI>Postnatal transmission of HIV associated with breast abscess</TI>
<SO>Lancet</SO>
<YR>1992</YR>
<VL>339</VL>
<PG>1490 &#8211;1491</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-de-Perre-1993" MODIFIED="2008-10-31 14:30:39 -0700" MODIFIED_BY="Tara Horvath" NAME="Van de Perre 1993" TYPE="JOURNAL_ARTICLE">
<AU>Van de Perre P, Simonon A, Hitimana DG, et al</AU>
<TI>Infective and anti-infective properties of breastmilk from HIV-infected women.</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>341 914 &#8211;918</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-der-Horst-2003" MODIFIED="2008-10-31 16:49:01 -0700" MODIFIED_BY="Tara Horvath" NAME="Van der Horst 2003" TYPE="JOURNAL_ARTICLE">
<AU>Van der Horst C, Fiscus S, Piwoz E, Corneli A, Moses A, Jones D, et al</AU>
<TI>Prevention of mother to infant transmission of HIV through breastfeeding and reduction of morbidity and mortality of the breastfeeding mothers: a study in Malawi</TI>
<SO>Antiviral Therapy</SO>
<YR>2003</YR>
<VL>8 (Suppl 1)</VL>
<PG>S4777</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-VanDerslice-1994" MODIFIED="2008-10-31 14:30:29 -0700" MODIFIED_BY="Tara Horvath" NAME="VanDerslice 1994" TYPE="JOURNAL_ARTICLE">
<AU>VanDerslice J, Popkin B, Briscoe J</AU>
<TI>Drinking-water quality, sanitation, and breast-feeding: their interactive effects on infant health.</TI>
<SO>Bull World Health Organ</SO>
<YR>1994</YR>
<VL>72</VL>
<PG>589&#8211;601</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Volmink-2007" NAME="Volmink 2007" TYPE="JOURNAL_ARTICLE">
<AU>Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P</AU>
<TI>Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection</TI>
<SO>Cochrane Database Syst Rev</SO>
<YR>2007</YR>
<VL>1</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2006" MODIFIED="2008-11-12 16:18:16 -0800" MODIFIED_BY="Tara Horvath" NAME="WHO 2006" TYPE="OTHER">
<AU>WHO HIV and Infant Feeding Technical Consultation, held on behalf of the Inter-agency Task Team (IATT) on Prevention of HIV Infections in Pregnant Women, Mothers and their Infants</AU>
<YR>Geneva, October 25-27, 2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-Team-2000" MODIFIED="2008-10-23 17:03:09 -0700" MODIFIED_BY="Tara Horvath" NAME="WHO Team 2000" TYPE="JOURNAL_ARTICLE">
<AU>WHO Collaborative Study Team on the Role of Breastfeeding on the Prevention of Infant Mortality</AU>
<TI>Effect of breastfeeding on infant and child mortality due to infectious diseases in less developed countries: a pooled analysis</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>355</VL>
<PG>451-455</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yoon-1996" MODIFIED="2008-10-31 14:30:00 -0700" MODIFIED_BY="Tara Horvath" NAME="Yoon 1996" TYPE="JOURNAL_ARTICLE">
<AU>Yoon PW, Black RE, Moulton LH, Becker S</AU>
<TI>Effect of not breastfeeding on the risk of diarrheal and respiratory mortality in children under 2 years of age in Metro Cebu, The Philippines.</TI>
<SO>Am J Epidemiol</SO>
<YR>1996</YR>
<VL>143 1142 &#8211;1148</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ziegler-1985" MODIFIED="2008-11-12 15:50:33 -0800" MODIFIED_BY="Tara Horvath" NAME="Ziegler 1985" TYPE="JOURNAL_ARTICLE">
<AU>Ziegler JB, Cooper DA, Johnson RO, Gold J</AU>
<TI>Postnatal transmission of AIDS-associated retrovirus from mother to infant</TI>
<SO>Lancet</SO>
<YR>1985</YR>
<VL>1 896 &#8211;898</VL>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-12-03 11:06:44 -0800" MODIFIED_BY="Tara Horvath">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-12-03 11:06:44 -0800" MODIFIED_BY="Tara Horvath" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-11-12 17:40:15 -0800" MODIFIED_BY="Tara Horvath" STUDY_ID="STD-Coovadia-2007">
<CHAR_METHODS MODIFIED="2008-11-07 14:59:40 -0800" MODIFIED_BY="Tara Horvath">
<P>Non-randomized intervention cohort study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-07 14:59:40 -0800" MODIFIED_BY="Tara Horvath">
<P>HIV-infected and uninfected pregnant women attending antenatal clinics in KwaZulu Natal were enrolled into a non-randomized intervention cohort study if they were 16 years of age or older, planned to stay in the study area for at least 3 months after delivery, and provided written informed consent.  Uninfected women were included to establish the effect of HIV status on adherence to exclusive breastfeeding and other infant feeding practices. </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-07 14:59:40 -0800" MODIFIED_BY="Tara Horvath">
<P>Exclusive breastfeeding (antenatal counseling regarding infant feeding options, home visits 3-4 times during first 2 weeks of life, and every 2 weeks thereafter until the infant was 6 months old. </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-12 17:40:15 -0800" MODIFIED_BY="Tara Horvath">
<P>HIV status:</P>
<P>1276 infants with complete feeding data. </P>
<P>14.1 (95%CI: 12.0-16.4) of exclusively breastfed infants infected with HIV by age 6 weeks and 19.5% (17.0-22.4) by 6 months;  the risk was significantly associated with maternal CD4 cell counts below 200 cells/mm<SUP>3</SUP> (adjusted HR 3.79; 2.35-6.12) and birth weight &lt; 2500 grams (1.81; 1.07-3.06).  Breast infants who also received solid food during their first six months of life were significantly more likely to acquire infection than were exclusively breastfed children (HR 10;87; 1.51-78.00; p=0.018), as were infants who at 12 weeks received both breast milk and formula milk (1.82; 0.98-3.36; p=0.057). </P>
<P>Mortality:</P>
<P>Cumulative 3-month mortality was15.1% (7.63-28.73) in infants given replacement feeds vs. 6.1% (4.74-7.92) among exclusively breastfed infants (HR 2.06; 1.00-4.27, p=0.51).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-07 14:59:33 -0800" MODIFIED_BY="Tara Horvath"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-12-03 11:04:20 -0800" MODIFIED_BY="Tara Horvath" STUDY_ID="STD-Fawzi-2002">
<CHAR_METHODS MODIFIED="2008-10-23 17:31:36 -0700" MODIFIED_BY="Tara Horvath">
<P>Randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-12-03 11:04:20 -0800" MODIFIED_BY="Tara Horvath">
<P>Pregnant women presenting to public antenatal clinics (in the era before interventions to prevent MTCT of HIV were available locally) between 12 and 27 weeks gestation who resided in Dar es Salaam, Tanzania, and who intended to stay in the city until after delivery and for at least 1 year thereafter were enrolled. Median age ~24 years;  CD4 count ~ 420</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-07 15:17:39 -0800" MODIFIED_BY="Tara Horvath">
<P>Eligible women were randomly assigned in a two-by-two factorial design to receive a daily oral dose of one or four regimens from enrolment and throughout the pregnancy and lactation periods:</P>
<OL>
<LI>vitamin A alone (30 mg beta-carotene plus 5000 IU preformed vitamin A)</LI>
<LI>multivitamins excluding vitamin A (20 mg B1, 20 mg B2, 25 mg B6, 100 mg niacin, 50 micrograms B12, 500 mg vitamin C, 30 mg vitamin E, 0.8 mg folic acid)</LI>
<LI>multivitamins including vitamin A in the same doses as above</LI>
<LI>placebo</LI>
</OL>
<P>At delivery, women in groups 1 and 3 received an additional oral dose of vitamin A (200,000 IU), and women in groups 2 and 4 received placebo.</P>
<P>Those infants whose mothers received multivitamins were compared to infants whose mothers did NOT receive multivitamins.  Similarly, those infants whose mothers received vitamin A were compared to infants whose mothers did NOT receive vitamin A.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-12 17:21:25 -0800" MODIFIED_BY="Tara Horvath">
<P>HIV infection status:</P>
<P>Multivitamins (vitamins B, C, and E) had no effect on the overall risk of HIV transmission (RR = 1.04; 95%CI: 0.82-1.32; p = 0.76).  Multivitamins were associated with non-statistically significant reductions in transmission through breastfeeding. </P>
<P>More cases of HIV infection were observed among children of mothers in the vitamin A arm compared with those who did not receive vitamin A  (RR=1.38; 95%CI: 1.09-1.76; p = 0.009). </P>
<P>Mortality:</P>
<P>Multivitamins (vitamins B, C, and E) had a modest and not statistically significant reduction in mortality by 24 months or the combined risks of infection and mortality among children. </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-12 17:41:22 -0800" MODIFIED_BY="Tara Horvath">
<P>Not all study details were provided in this publication.  "Details of the study design have been published [9,10]" (referring to <LINK REF="REF-Fawzi-2000" TYPE="REFERENCE">Fawzi 2000</LINK> and <LINK REF="REF-Fawzi-1998" TYPE="REFERENCE">Fawzi 1998</LINK>). <LINK REF="REF-Fawzi-2000" TYPE="REFERENCE">Fawzi 2000</LINK> says: "Details of the study design have been published elsewhere (10,11)" (referring to <LINK REF="REF-Fawzi-1999" TYPE="REFERENCE">Fawzi 1999</LINK> and <LINK REF="REF-Fawzi-1998" TYPE="REFERENCE">Fawzi 1998</LINK>).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-12-03 11:04:41 -0800" MODIFIED_BY="Tara Horvath" STUDY_ID="STD-Kuhn-2008">
<CHAR_METHODS MODIFIED="2008-11-07 15:01:33 -0800" MODIFIED_BY="Tara Horvath">
<P>Randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-12-03 11:04:41 -0800" MODIFIED_BY="Tara Horvath">
<P>HIV-infected women were recruited from two antenatal clinics in Lusaka, Zambia that offered VCT and the two dose nevirapine prophylaxis regimen (one dose to mother, one dose to infant) prophylaxis.  Pregnant women (less than 38 weeks gestation) were recruited.  Women could volunteer if they intended to breastfeed for any length of time, accepted treatment with nevirapine, and agreed to be randomly assigned to the intervention or control group.  Exclusion criteria were severe pregnancy complications (e.g., pre-eclampsia), previous cesarean delivery, and HIV-related conditions requiring hospitalization.</P>
<P>Median CD4 count of mothers at baseline was ~330 cells/mm3.  The maternal plasma viral load (median) was about 36,000-41,000 copies/mL.  Slightly over a third of the women were eligible for antiretroviral therapy.  The mean age was 26 years.  84-85% were married.  Over half of mothers had no schooling or only primary school education.</P>
<P>3216 women and 3276 infants were enrolled, and infants underwent randomization at birth;  of 3276 infants assigned an intervention, 3106 were included in the primary analysis;  of these, 2389 reached the HIV infection endpoint OR did not have HIV infection and were under follow-up or completed follow-up.</P>
<P>Median maternal age was ~26 years.  ~2/3 had &lt; grade 8 education;  median CD4 count was ~400; ~2/3 presented early (&gt;4 hours before delivery)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-07 15:01:33 -0800" MODIFIED_BY="Tara Horvath">
<P>Early, abrupt weaning</P>
<P>Participants were randomly assigned to one of two groups.  The experimental intervention encouraged women to breastfeed exclusively to 4 months and then to stop breastfeeding abruptly, or as rapidly as possible.  Women in the control group were encouraged to breastfeed exclusively to 6 months, gradually introduce complementary foods, and continue to breastfeed for a duration of their own choice (standard practice).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-07 15:01:33 -0800" MODIFIED_BY="Tara Horvath">
<P>Child mortality rates were similar by 24 months in the two groups:  23.9% in the intervention group and 24.6% in the control group (p = 0.96). </P>
<P>There was no significant difference in HIV-free survival between the two groups according to the intention-to-treat analysis:  at 24 months of age, 68.4% of children in the intervention group and 64.0% in the control group were alive and not infected with HIV (p = 0.13)</P>
<P>Among uninfected children who were still being breastfed at 4 months, there was no significant difference between the groups in HIV-free survival at 24 months:  83.9% of the children in the intervention group survived to 24 months without HIV infection, as compared with 80.7% in the control group (p = 0.27).  Between 4 and 24 months, rates of postnatal HIV transmission were not significantly different (6.2% in the intervention group and 8.8% in the control group, p = 0.19), and mortality among uninfected children was similar in the two groups (0.7% in the intervention group and 11.7% in the control group, p = 0.71). </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-07 15:01:24 -0800" MODIFIED_BY="Tara Horvath"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-12-03 11:05:40 -0800" MODIFIED_BY="Tara Horvath" STUDY_ID="STD-Kumwenda-2008">
<CHAR_METHODS MODIFIED="2008-11-07 15:02:40 -0800" MODIFIED_BY="Tara Horvath">
<P>Randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-12-03 11:05:05 -0800" MODIFIED_BY="Tara Horvath">
<P>Pregnant women who presented for either antenatal or delivery services at specific health centers in Blantyre, Malawi were offered HIV counseling and testing.  All women with HIV infection, except those late presenters whose HIV infection was not identified until after they gave birth, received a single intrapartum dose of nevirapine.  Women could be enrolled in the trial if they had HIV infection, were at least 18 years of age (although women &lt;18 years of age could be enrolled if they consented and a guardian gave permission), were pregnant or had given birth within the previous 24 hours at one of the study clinics, were a resident of the study area, were willing to return for postnatal follow-up visits for up to 2 years, and intended to breastfeed.  The study excluded infants with life-threatening conditions requiring immediate care.  Mothers were counseled to breastfeed exclusively for six months and to consider weaning thereafter.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-03 11:05:40 -0800" MODIFIED_BY="Tara Horvath">
<P>Arm 1:  single dose nevirapine PLUS 1 week of zidovudine (control regimen)</P>
<P>Arm 2:  control regimen PLUS daily nevirapine starting at age 7 days until the age of 14 weeks</P>
<P>Arm 3:  control regimen PLUS daily nevirapine with zidovudine starting at age 7 days until the age of 14 weeks</P>
<P>The control regimen was single dose nevirapine PLUS 1 week of zidovudine. (Those women who enrolled early enough received one dose of intrapartum nevirapine; some women (approximately 30%) presented too late to receive intrapartum nevirapine.)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-07 15:14:30 -0800" MODIFIED_BY="Tara Horvath">
<P>HIV infection status:</P>
<P>Of 3016 infants, 255 were found to have HIV infection (242 confirmed and 13 presumptive).</P>
<P>Among infants who were not infected at birth, between the ages of 6 weeks and 18 months, the control group had consistently higher rates of HIV infection, as compared with both extended-prophylaxis groups. </P>
<P>At 9 months, the estimated rate of HIV infection (primary end point) was 10.6% in the control group, 5.2% extended nevirapine group (P &lt; 0.001), 6.4% in extended dual prophylaxis group (P = 0.002).  There were no significant differences between the two extended-prophylaxis groups. </P>
<P>The estimated protective efficacy of the extended prophylaxis regimens were:</P>
<P>6 weeks:   </P>
<UL>
<LI>Nevirapine:  67% (95%CI: 43-81)</LI>
<LI>Nevirapine + Zidovudine:  69% (95%CI: 45-83)</LI>
</UL>
<P>14 weeks: </P>
<UL>
<LI>Nevirapine:  67% (95%CI: 49-79)</LI>
<LI>Nevirapine + Zidovudine:  66% (95%CI: 48-78)</LI>
</UL>
<P>6 months: </P>
<UL>
<LI>Nevirapine:   60% (95%CI: 42-73)</LI>
<LI>Nevirapine + Zidovudine:  49% (95%CI: 27-64)</LI>
</UL>
<P>9 months: </P>
<UL>
<LI>Nevirapine:   51% (95%CI: 30-66)       </LI>
<LI>Nevirapine + Zidovudine:  40% (95%CI: 16-57)</LI>
</UL>
<P>Mortality:</P>
<P>No statistically significant differences in mortality by study arm.</P>
<P>HIV-free survival was significantly better through the age of 9 months in both extended prophylaxis groups, and through the age of 15 months in the extended nevirapine group.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-07 15:02:40 -0800" MODIFIED_BY="Tara Horvath">
<P>Adverse effects:</P>
<P>Infants receiving nevirapine + zidovudine prophylaxis had a significant increase in the number of adverse events (primarily neutropenia) deemed possibly related to a study drug.  There was no difference in adverse events between the control group and the nevirapine only prophylaxis group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-12-03 11:06:00 -0800" MODIFIED_BY="Tara Horvath" STUDY_ID="STD-Nduati-2000">
<CHAR_METHODS MODIFIED="2008-11-07 15:03:21 -0800" MODIFIED_BY="Tara Horvath">
<P>Randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-12-03 11:06:00 -0800" MODIFIED_BY="Tara Horvath">
<P>Pregnant women attending 4 Nairobi antenatal clinics (in the era before interventions to prevent MTCT of HIV were available locally) were offered counseling and serologic testing for HIV.  Seropositive women were invited to attend the research clinic at Kenyatta National Hospital.  Women were eligible if they resided in Nairobi and had access to municipal-treated water.  Women were randomized to breastfeed or formula feed at about 32 weeks.   </P>
<P>Of 2315 HIV seropositive women, 1708 (74%) returned to receive their results.  Of these, 425 (25%) were enrolled (18% of all seropositive pregnant women). </P>
<P>Median age of enrolled women = 23 years.  61% of women living in a 1-room home, 74% sharing a toilet with other households, 5% owning a refrigerator.  All women had access to clean water, 76% had access to flush sanitation.  At 32 weeks gestation, 47/381 women (12%) had CD4 &lt; 200 cells/mm3.  Median plasma viral load at this visit was 42,360 copies/mL. </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-07 15:03:21 -0800" MODIFIED_BY="Tara Horvath">
<P>Formula feeding instead of breastfeeding. Those randomized to formula feeding were compared to those randomized to breastfeeding.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-07 15:10:59 -0800" MODIFIED_BY="Tara Horvath">
<P>HIV status:</P>
<P>The cumulative probability of HIV infection at 24 months was 36.7% (95% CI: 29.4-44.0%) in the breastfeeding arm and 20.5% (95%CI: 14.0-27.0%) in the formula arm (p = 0.001).</P>
<P>Morbidity:</P>
<P>
<LINK REF="REF-Mbori_x002d_Ngacha-2001" TYPE="REFERENCE">Mbori-Ngacha 2001</LINK> addresses morbidity:</P>
<P>Of 401 live born, singleton or first-born twin infants of randomized HIV-seropositive mothers, 371 were included in the analysis of morbidity and mortality. </P>
<P>Incidence of diarrhea during the 2 years of follow-up was similar in formula and breastfeeding arms (155 vs 149 per 100 person-years, respectively).  The incidence of pneumonia was identical in the 2 groups (62/100 person years).  There were no significant differences in incidence of other recorded illnesses.</P>
<P>Mortality</P>
<P>The 2-year mortality rates in both arms were similar: (breastfeeding arm:  24.4% (95%CI: 18.2-30.7%) vs. formula feeding arm: 20.0% (95%CI: 14.4-25.6%); p = 0.30</P>
<P>The rate of HIV-free survival at 2 years was significantly lower in the breastfeeding arm than in the formula feeding arm (58.0% vs. 70.0%, respectively, p = 0.02).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-07 15:03:17 -0800" MODIFIED_BY="Tara Horvath"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-12-03 11:06:25 -0800" MODIFIED_BY="Tara Horvath" STUDY_ID="STD-SWEN-2008">
<CHAR_METHODS MODIFIED="2008-10-23 17:36:23 -0700" MODIFIED_BY="Tara Horvath">
<P>Randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-12 17:45:39 -0800" MODIFIED_BY="Tara Horvath">
<P>Pregnant women who presented to antenatal and delivery facilities in Addis Ababa, Ethiopia, Pune, India, and Kampala, Uganda, who were identified as HIV-infected, were offered the local standard of care for prevention of MTCT of HIV and provided infant feeding counseling, consistent with WHO/UNICEF guidelines. Women were eligible for study enrolment if they indicated an intention to breastfeed their infants and provided informed consent.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-03 11:06:25 -0800" MODIFIED_BY="Tara Horvath">
<P>In Arm 1 (control arm) of the trials, 200 mg nevirapine was provided to women in labor and 2 mg/kg to infants shortly after birth.  In Arm 2 of the trials, this two-dose nevirapine regimen was provided in addition to infant dosing of 5 mg nevirapine each day starting at age 7 days through six weeks of life.  The risk of HIV infection and death at 6 weeks and 6 months of age in infants who were HIV-uninfected at birth was estimated.  The analysis included data for 1887 infants. </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-12 14:46:49 -0800" MODIFIED_BY="Tara Horvath">
<P>At six weeks of age, more children in the single-dose nevirapine group than the extended-dose nevirapine group were infected (relative risk:  0.54; 0.34-0.86; p=0.009).  However, at six months of age, the risk of transmission was similar (relative risk 0.80; 0.58-1.10; p=0.16).  HIV-free survival was higher in the extended prophylaxis arm, at both six weeks (p = 0.008) and six months (p = 0.03). </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-07 15:34:42 -0800" MODIFIED_BY="Tara Horvath"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-12-03 11:06:44 -0800" MODIFIED_BY="Tara Horvath" STUDY_ID="STD-Thior-2006">
<CHAR_METHODS MODIFIED="2008-11-07 15:06:04 -0800" MODIFIED_BY="Tara Horvath">
<P>Randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-07 15:06:04 -0800" MODIFIED_BY="Tara Horvath">
<P>1200 HIV-infected women were randomized.  Primary efficacy (HIV infection by age 7 months and HIV-free survival by age 18 months) and safety (occurrence of infant adverse events by 7 months of age) end points were evaluated in 1179 infants. Median maternal age = 26.78 years; 55% had water tap in the yard, 37% used communal standpipe; 74% cited private latrine/house as the most used sanitation facility; 24% had electricity in the home; the maternal baseline CD4 count was 366 cells/mm3 and the median maternal baseline plasma viral load was 4.35 log10 copies/mL</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-03 11:06:44 -0800" MODIFIED_BY="Tara Horvath">
<P>Mothers were instructed to initiate and complete weaning when the infant was between five and six months of age.  Infants were randomized to 6 months of breastfeeding plus prophylactic infant zidovudine (breastfed plus 6 months of zidovudine) or formula feeding plus 1 month of infant zidovudine (formula fed). Infants received zidovudine syrup 4 mg/kg/12 hours from birth until 1 month of age in all infants, and discontinued at 1 month in the formula-fed group.  For the breastfed plus zidovudine group, infant zidovudine prophylaxis continued from 1 to 2 months of age at 4 mg/kg/8 hours, and from 2 to 6 months of age (while still breastfeeding) at 6 mg/kg/8 hours.</P>
<P>(All mothers received zidovudine 300 mg orally twice daily from 34 weeks gestation and during labor.). </P>
<P>Mothers and infants were randomized to receive single-dose nevirapine or placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-07 15:06:04 -0800" MODIFIED_BY="Tara Horvath">
<P>Morbidity:</P>
<P>The rates of grade 3 or higher signs or symptoms (17.6% vs. 13.1%; P = 0.03) and of hospitalization (20.3% vs. 15.6%, P = 0.04) by 7 months were significantly higher among infants in the formula-fed group than in the breastfed plus zidovudine group.  </P>
<P>Mortality:</P>
<P>Cumulative mortality or HIV infection rates at 18 months were 80 infants (13.9%, formula fed) vs. 86 infants (15.1% breastfed plus zidovudine) (P = 0.60). </P>
<P>Cumulative infant mortality at 7 months was significantly higher for the formula-fed group than for the breastfed plus zidovudine group (9.3% vs. 4.9%; p = 0.003), but this difference diminished beyond month 7 such that the time-to-mortality distributions through age 18 months were not significantly different (P = 0.21). </P>
<P>Therefore, breastfeeding with zidovudine prophylaxis for six months was associated with a lower mortality rate at 7 months, but both strategies had comparable HIV-free survival at 18 months.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-07 15:06:04 -0800" MODIFIED_BY="Tara Horvath">
<P>Adverse effects:</P>
<P>The rate of grade 3 or higher laboratory abnormality associated with zidovudine toxicity was significantly higher in the breastfed plus zidovudine group than in the formula-fed group (24.7% vs. 14.8%) (P &lt; 0.001).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-11-07 15:09:05 -0800" MODIFIED_BY="Tara Horvath" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-11-07 15:08:22 -0800" MODIFIED_BY="Tara Horvath" STUDY_ID="STD-Becquet-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-07 15:08:22 -0800" MODIFIED_BY="Tara Horvath">
<P>Not a randomized clinical trial (prospective cohort study); mothers had received antiretrovirals perinatally.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-07 15:08:27 -0800" MODIFIED_BY="Tara Horvath" STUDY_ID="STD-Becquet-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-07 15:08:27 -0800" MODIFIED_BY="Tara Horvath">
<P>Not a randomized clinical trial (open-labeled cohort study); mothers had received antiretrovirals perinatally.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-07 15:08:31 -0800" MODIFIED_BY="Tara Horvath" STUDY_ID="STD-Bobat-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-07 15:08:31 -0800" MODIFIED_BY="Tara Horvath">
<P>Not a randomized clinical trial (prospective cohort study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-07 15:07:10 -0800" MODIFIED_BY="Tara Horvath" STUDY_ID="STD-Dabis-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-07 15:07:10 -0800" MODIFIED_BY="Tara Horvath">
<P>This study addressed in utero/intrapartum transmission (not a trial addressing prevention of late postnatal transmission)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-07 15:08:18 -0800" MODIFIED_BY="Tara Horvath" STUDY_ID="STD-Embree-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-07 15:08:18 -0800" MODIFIED_BY="Tara Horvath">
<P>Not a randomized clinical trial (longitudinal observational cohort study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-07 15:07:22 -0800" MODIFIED_BY="Tara Horvath" STUDY_ID="STD-Gray-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-07 15:07:22 -0800" MODIFIED_BY="Tara Horvath">
<P>This study addresses prevention of peripartum transmission of HIV.  Was not designed (and did not address) late postnatal/breastfeeding transmission of HIV.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-07 15:07:35 -0800" MODIFIED_BY="Tara Horvath" STUDY_ID="STD-Guay-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-07 15:07:35 -0800" MODIFIED_BY="Tara Horvath">
<P>This study addressed in utero/intrapartum transmission (not a trial addressing prevention of late postnatal transmission)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-07 15:07:48 -0800" MODIFIED_BY="Tara Horvath" STUDY_ID="STD-Iliff-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-07 15:07:48 -0800" MODIFIED_BY="Tara Horvath">
<P>This is analysis of data regarding infant feeding (data came from a randomized trial addressing a different topic), i.e., this is an analysis of prospectively collected data regarding infant feeding modalities and infant HIV infection status.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-07 15:08:40 -0800" MODIFIED_BY="Tara Horvath" STUDY_ID="STD-Kilewo-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-07 15:08:40 -0800" MODIFIED_BY="Tara Horvath">
<P>Not a randomized clinical trial (prospective cohort study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-07 15:08:44 -0800" MODIFIED_BY="Tara Horvath" STUDY_ID="STD-Miotti-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-07 15:08:44 -0800" MODIFIED_BY="Tara Horvath">
<P>Not a randomized clinical trial (prospective cohort study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-07 15:09:05 -0800" MODIFIED_BY="Tara Horvath" STUDY_ID="STD-SIMBA-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-07 15:09:05 -0800" MODIFIED_BY="Tara Horvath">
<P>Abstract only - manuscript was never published.  Authors of the study were contacted, but no further information was obtained.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-12-03 11:15:39 -0800" MODIFIED_BY="Tara Horvath">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2008-12-03 11:15:15 -0800" MODIFIED_BY="Tara Horvath" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-07 14:56:55 -0800" MODIFIED_BY="Tara Horvath" RESULT="NO" STUDY_ID="STD-Coovadia-2007">
<DESCRIPTION>
<P>Not a randomized controlled trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-29 12:56:32 -0700" MODIFIED_BY="Tara Horvath" RESULT="UNKNOWN" STUDY_ID="STD-Fawzi-2002">
<DESCRIPTION>
<P>"We assigned women randomly to receive a daily oral dose." (From <LINK REF="REF-Fawzi-1999" TYPE="REFERENCE">Fawzi 1999</LINK>)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-07 14:56:55 -0800" MODIFIED_BY="Tara Horvath" RESULT="YES" STUDY_ID="STD-Kuhn-2008">
<DESCRIPTION>
<P>Use of a computer algorithm with randomized permuted block design within each site</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-03 11:15:15 -0800" MODIFIED_BY="Tara Horvath" RESULT="YES" STUDY_ID="STD-Kumwenda-2008">
<DESCRIPTION>
<P>"Randomization procedures employed permutated block algorithms of sizes 9 and 12, stratified by study clinic. A computer generated randomization list assigned infants to the appropriate treatment arms using a 1:1:1 allocation ratio. Randomization numbers were placed in sequentially labeled and sealed envelopes." (From <LINK REF="STD-Kumwenda-2008" TYPE="STUDY">Kumwenda 2008</LINK>)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-07 15:03:50 -0800" MODIFIED_BY="Tara Horvath" RESULT="YES" STUDY_ID="STD-Nduati-2000">
<DESCRIPTION>
<P>"Women were randomized to breastfeed or formula feed at about 32 weeks using computer-generated block randomization."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-12 17:18:54 -0800" MODIFIED_BY="Tara Horvath" RESULT="YES" STUDY_ID="STD-SWEN-2008">
<DESCRIPTION>
<P>"For all three countries, block randomisation was used with treatment assignments generated by computer at a central data coordinating centre at Johns Hopkins University. The randomisation list was provided to study pharmacists only in each country."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-07 15:06:33 -0800" MODIFIED_BY="Tara Horvath" RESULT="YES" STUDY_ID="STD-Thior-2006">
<DESCRIPTION>
<P>Centralized randomization to both part 1 and part 2 groups occurred at study enrolment (34 weeks gestation), using permuted blocks of size 8 within each site.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-11-07 15:16:27 -0800" MODIFIED_BY="Tara Horvath" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-07 14:56:55 -0800" MODIFIED_BY="Tara Horvath" RESULT="NO" STUDY_ID="STD-Coovadia-2007">
<DESCRIPTION>
<P>Not a randomized controlled trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-28 14:15:30 -0700" MODIFIED_BY="Tara Horvath" RESULT="NO" STUDY_ID="STD-Fawzi-2002">
<DESCRIPTION>
<P>Not addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-31 15:13:51 -0700" MODIFIED_BY="Tara Horvath" RESULT="NO" STUDY_ID="STD-Kuhn-2008">
<DESCRIPTION>
<P>"Participants were informed of their assignment at the next (usually second-month) visit to ensure sufficient time for preparation."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-31 15:19:22 -0700" MODIFIED_BY="Tara Horvath" RESULT="NO" STUDY_ID="STD-Kumwenda-2008">
<DESCRIPTION>
<P>Not addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-07 15:03:50 -0800" MODIFIED_BY="Tara Horvath" RESULT="NO" STUDY_ID="STD-Nduati-2000">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-07 15:16:27 -0800" MODIFIED_BY="Tara Horvath" RESULT="UNKNOWN" STUDY_ID="STD-SWEN-2008">
<DESCRIPTION>
<P>"Study products were administered by pre-filled amber oral syringes in Ethiopia and Uganda and by opaque dropper bottles in India, after training of mothers by study pharmacists .A number of specific study procedures were implemented to introduce some degree of masking of study staff and care givers. Specifically, none of the study investigators or staff, with the exception of the study pharmacists and a member of the central data management team, had access to the randomization assignments for study participants." Because study pharmacists knew the randomization assignments, however, and worked directly with the mothers, it is possible that allocation was not sufficiently well concealed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-07 15:06:42 -0800" MODIFIED_BY="Tara Horvath" RESULT="UNKNOWN" STUDY_ID="STD-Thior-2006">
<DESCRIPTION>
<P>Probably done, but exactly how is unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2008-11-12 17:18:37 -0800" MODIFIED_BY="Tara Horvath" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-23 17:31:05 -0700" MODIFIED_BY="Tara Horvath" RESULT="NO" STUDY_ID="STD-Coovadia-2007">
<DESCRIPTION>
<P>This study was not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-11-12 16:55:38 -0800" MODIFIED_BY="Tara Horvath" RESULT="YES" STUDY_ID="STD-Fawzi-2002">
<DESCRIPTION>
<P>"We realized that unblinding, whether real or based on an impression or perception that may develop among subjects or staff, is more likely to occur if regimens are color-coded or bear simple numeric codes. To minimize this risk, we provided the regimen in bottles labeled with the subjects&#8217; names and identification numbers, and made active tablets and placebo indistinguishable, so that neither the subjects nor the investigators could identify which subjects were randomized to the same regimen." (From <LINK REF="REF-Fawzi-1999" TYPE="REFERENCE">Fawzi 1999</LINK>)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-23 17:33:34 -0700" MODIFIED_BY="Tara Horvath" RESULT="NO" STUDY_ID="STD-Kuhn-2008">
<DESCRIPTION>
<P>This study was not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-23 17:34:49 -0700" MODIFIED_BY="Tara Horvath" RESULT="NO" STUDY_ID="STD-Kumwenda-2008">
<DESCRIPTION>
<P>This study was not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-11-07 15:03:50 -0800" MODIFIED_BY="Tara Horvath" RESULT="NO" STUDY_ID="STD-Nduati-2000">
<DESCRIPTION>
<P>This study was not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-11-12 17:18:37 -0800" MODIFIED_BY="Tara Horvath" RESULT="NO" STUDY_ID="STD-SWEN-2008">
<DESCRIPTION>
<P>"This study was not blinded"; However, "[t]he reliability of the HIV PCR results were assessed through a centralised quality assurance programme, coordinated by the laboratory of one of the authors (JBJ) at Johns Hopkins School of Medicine, which included blinded retesting of samples from HIV-infected infants and a random sample of HIV-uninfected infants. Final infant infection status was assigned for each country by a blinded study investigator and results from all three countries were subsequently reviewed by a fourth blinded investigator (JBJ) to ensure consistency across the countries.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-11-07 15:06:33 -0800" MODIFIED_BY="Tara Horvath" RESULT="NO" STUDY_ID="STD-Thior-2006">
<DESCRIPTION>
<P>This study was not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2008-12-03 11:15:39 -0800" MODIFIED_BY="Tara Horvath" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-10-31 15:04:57 -0700" MODIFIED_BY="Tara Horvath" RESULT="YES" STUDY_ID="STD-Coovadia-2007">
<DESCRIPTION>
<P>"Data for nevirapine uptake and ingestion were inconsistent and are not included in any analysis."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-03 11:15:39 -0800" MODIFIED_BY="Tara Horvath" RESULT="YES" STUDY_ID="STD-Fawzi-2002">
<DESCRIPTION>
<P>"We also developed a system for tracking the survival of all women not in active follow-up, by visiting their homes regularly and asking questions of neighbors, relatives, and friends. Through these methods, we have kept loss to follow-up down to about 5% per year. We anticipated these inevitable losses, and other losses due to mortality, and factored them in our sample-size calculation." (From <LINK REF="REF-Fawzi-1999" TYPE="REFERENCE">Fawzi 1999</LINK>)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-11-07 15:01:58 -0800" MODIFIED_BY="Tara Horvath" RESULT="YES" STUDY_ID="STD-Kuhn-2008">
<DESCRIPTION>
<P>"Home-visit teams tracked the participants who did not return for appointments. Information about children&#8217;s deaths was sought from hospital and clinic records and from interviews with caretakers and health care personnel. The circumstances of all deaths were reviewed to identify the causes of death."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-11-07 15:10:59 -0800" MODIFIED_BY="Tara Horvath" RESULT="YES" STUDY_ID="STD-Kumwenda-2008">
<DESCRIPTION>
<P>"All Grade 3-4 toxicities, rashes Grade 2B or higher and ALT levels Grade 2 or higher were considered serious. Serious adverse events, including deaths and hospitalizations, were reported to the University of Malawi, Johns Hopkins University, and CDC Institutional Review Boards (IRBs). Abnormal clinical and laboratory findings were followed until resolution to Grade 2 or lower. Infants discontinued from study drug(s) were followed for the study duration." (From <LINK REF="STD-Kumwenda-2008" TYPE="STUDY">Kumwenda 2008</LINK>
<LINK REF="REF-Kumwenda-2008-Supplement" TYPE="REFERENCE"> Supplement</LINK>)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-11-07 15:03:50 -0800" MODIFIED_BY="Tara Horvath" RESULT="YES" STUDY_ID="STD-Nduati-2000">
<DESCRIPTION>
<P>"We did not present secondary analyses of self-reported feeding behavior and HIV transmission or mortality, because feeding practices may be associated with confounding variables that affect primary study outcomes."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-11-12 17:46:51 -0800" MODIFIED_BY="Tara Horvath" RESULT="YES" STUDY_ID="STD-SWEN-2008">
<DESCRIPTION>
<P>"Since many infant deaths occurred at home or outside of the study clinics, information about the cause of these deaths was limited to verbal autopsy interviews of mothers and other family members. Thus, HIV status at the time of death was not available for infants who could have become HIV positive between their last study visit and their death. 38 (72%) of the deaths occurred among infants for whom their last HIV screening test was negative by HIV PCR. However, the mean time from this last study visit until death was 13·8 (SD 17·7) days, decreasing the likelihood that we failed to identify HIV-infected infants before their death. We assessed the distribution of mortality by sex, because of an imbalance between study groups at baseline, but there was no significant difference between males and females in terms of the distribution of overall mortality (data not shown). We found no differences between groups in other factors that might be associated with infant mortality, including maternal age, maternal CD4 cell count, maternal viral load (available in India and Uganda), maternal education level, parity, gravidity, and gestational age at enrolment (data not shown)."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-11-07 15:06:33 -0800" MODIFIED_BY="Tara Horvath" RESULT="NO" STUDY_ID="STD-Thior-2006">
<DESCRIPTION>
<P>Not addressed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2008-11-12 17:34:51 -0800" MODIFIED_BY="Tara Horvath" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-12 16:53:10 -0800" MODIFIED_BY="Tara Horvath" RESULT="YES" STUDY_ID="STD-Coovadia-2007">
<DESCRIPTION>
<P>No problems apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-31 16:07:35 -0700" MODIFIED_BY="Tara Horvath" RESULT="YES" STUDY_ID="STD-Fawzi-2002">
<DESCRIPTION>
<P>No problems apparent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-31 15:16:52 -0700" MODIFIED_BY="Tara Horvath" RESULT="YES" STUDY_ID="STD-Kuhn-2008">
<DESCRIPTION>
<P>No problems apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-31 15:27:22 -0700" MODIFIED_BY="Tara Horvath" RESULT="YES" STUDY_ID="STD-Kumwenda-2008">
<DESCRIPTION>
<P>No problems apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-07 15:03:50 -0800" MODIFIED_BY="Tara Horvath" RESULT="YES" STUDY_ID="STD-Nduati-2000">
<DESCRIPTION>
<P>No problems apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-12 17:34:51 -0800" MODIFIED_BY="Tara Horvath" RESULT="YES" STUDY_ID="STD-SWEN-2008">
<DESCRIPTION>
<P>No problems apparent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-07 15:06:33 -0800" MODIFIED_BY="Tara Horvath" RESULT="UNKNOWN" STUDY_ID="STD-Thior-2006">
<DESCRIPTION>
<P>Possibly some post-randomization selection bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2008-11-12 16:56:01 -0800" MODIFIED_BY="Tara Horvath" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-12 16:53:22 -0800" MODIFIED_BY="Tara Horvath" RESULT="YES" STUDY_ID="STD-Coovadia-2007">
<DESCRIPTION>
<P>No problems apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-31 16:26:03 -0700" MODIFIED_BY="Tara Horvath" RESULT="YES" STUDY_ID="STD-Fawzi-2002">
<DESCRIPTION>
<P>No problems apparent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-12 16:56:01 -0800" MODIFIED_BY="Tara Horvath" RESULT="YES" STUDY_ID="STD-Kuhn-2008">
<DESCRIPTION>
<P>No problems apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-29 14:54:26 -0700" MODIFIED_BY="Tara Horvath" RESULT="YES" STUDY_ID="STD-Kumwenda-2008">
<DESCRIPTION>
<P>No problems apparent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-07 15:03:50 -0800" MODIFIED_BY="Tara Horvath" RESULT="UNKNOWN" STUDY_ID="STD-Nduati-2000">
<DESCRIPTION>
<P>"Because more than one quarter of women in the formula arm admitted to noncompliance with feeding modality, our estimated breast milk transmission rate is an underestimate."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-29 14:54:01 -0700" MODIFIED_BY="Tara Horvath" RESULT="YES" STUDY_ID="STD-SWEN-2008">
<DESCRIPTION>
<P>No problems apparent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-07 15:06:33 -0800" MODIFIED_BY="Tara Horvath" RESULT="YES" STUDY_ID="STD-Thior-2006">
<DESCRIPTION>
<P>No problems apparent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2008-10-23 17:30:12 -0700" MODIFIED_BY="Tara Horvath" NO="7">
<NAME>Something else!</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-10-30 16:41:46 -0700" MODIFIED_BY="Tara Horvath">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-10-30 16:41:46 -0700" MODIFIED_BY="Tara Horvath" NO="1">
<TITLE MODIFIED="2008-10-30 16:41:46 -0700" MODIFIED_BY="Tara Horvath">Examples of search strategies</TITLE>
<TABLE COLS="2" ROWS="32">
<TR>
<TD COLSPAN="2">
<P>
<B>PubMED: Date range: 1 January 1980 - 15 July 2008</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>#11</P>
</TD>
<TD>
<P>Search <B>#3 AND #4 AND #9</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>#10</P>
</TD>
<TD>
<P>Search <B>#3 AND #4 AND #9</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>#9</P>
</TD>
<TD>
<P>Search <B>#7 OR #8</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>#8</P>
</TD>
<TD>
<P>Search <B>(infant feeding) OR (infant nutrition) OR (infant feeding options) OR (exclusive breastfeeding) OR (exclusive breast-feeding) OR (exclusive breast feeding) OR (formula feeding) OR (early weaning) OR (abrupt weaning) OR (wet nursing) OR (milk bank) OR (milk banks) OR (expressed breast milk) OR (expressed human milk) OR (replacement feeding)</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>#7</P>
</TD>
<TD>
<P>Search <B>#5 AND #6</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>#6</P>
</TD>
<TD>
<P>Search <B>pasteurization OR pasteurization OR (heat treatment) OR sterilisation OR sterilization OR decontamination</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P>Search <B>(breast milk) OR (breast milks) OR (human milk)</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>Search <B>(mother-to-child transmission) OR (mother to child transmission) OR (adult-to-child transmission) OR (adult to child transmission) OR (maternal-to-child transmission) OR (maternal to child transmission) OR (breast milk transmission) OR (breast-milk transmission) OR (vertical transmission) OR (disease transmission, vertical)</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>Search <B>#1 AND #2</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>Search <B>randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh] OR double-blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR ("clinical trial" [tw]) OR ((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR ( placebos [mh] OR placebo* [tw] OR random* [tw] OR research design [mh:noexp] OR comparative study [mh] OR evaluation studies [mh] OR follow-up studies [mh] OR prospective studies [mh] OR control* [tw] OR prospectiv* [tw] OR volunteer* [tw]) NOT (animals [mh] NOT human [mh])</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P>Search <B>HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tw] OR hiv-1*[tw] OR hiv-2*[tw] OR hiv1[tw] OR hiv2[tw] OR hiv infect*[tw] OR human immunodeficiency virus[tw] OR human immunedeficiency virus[tw] OR human immuno-deficiency virus[tw] OR human immune-deficiency virus[tw] OR ((human immun*) AND (deficiency virus[tw])) OR acquired immunodeficiency syndrome[tw] OR acquired immunedeficiency syndrome[tw] OR acquired immuno-deficiency syndrome[tw] OR acquired immune-deficiency syndrome[tw] OR ((acquired immun*) AND (deficiency syndrome[tw])) OR "sexually transmitted diseases, viral"[MESH:NoExp]</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>EMBASE: Date range: 1 January 1980 - 15 July 2008</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P>((((<B>'human immunodeficiency virus infection'</B>/exp OR <B>'human immunodeficiency virus infection'</B>) OR (<B>'human immunodeficiency virus infection'</B>/exp OR <B>'human immunodeficiency virus infection'</B>)) OR ((<B>'human immunodeficiency virus infection'</B>/exp OR <B>'human immunodeficiency virus infection'</B>) OR (<B>'human immunodeficiency virus infection'</B>/exp OR <B>'human immunodeficiency virus infection'</B>))) OR (((<B>'human immunodeficiency virus infection'</B>/exp OR <B>'human immunodeficiency virus infection'</B>) OR (<B>'human immunodeficiency virus infection'</B>/exp OR <B>'human immunodeficiency virus infection'</B>)) OR ((<B>'human immunodeficiency virus infection'</B>/exp OR <B>'human immunodeficiency virus infection'</B>) OR (<B>'human immunodeficiency virus infection'</B>/exp OR <B>'human immunodeficiency virus infection'</B>)))) OR (((((<B>'human immunodeficiency virus'</B>/exp OR <B>'human immunodeficiency virus'</B>) OR (<B>'human immunodeficiency virus'</B>/exp OR <B>'human immunodeficiency virus'</B>)) OR ((<B>'human immunodeficiency virus'</B>/exp OR <B>'human immunodeficiency virus'</B>) OR (<B>'human immunodeficiency virus'</B>/exp OR <B>'human immunodeficiency virus'</B>))) OR (((<B>'human immunodeficiency virus'</B>/exp OR <B>'human immunodeficiency virus'</B>) OR (<B>'human immunodeficiency virus'</B>/exp OR <B>'human immunodeficiency virus'</B>)) OR ((<B>'human immunodeficiency virus'</B>/exp OR <B>'human immunodeficiency virus'</B>) OR (<B>'human immunodeficiency virus'</B>/exp OR <B>'human immunodeficiency virus'</B>))))) OR (<B>hiv</B>:ti OR <B>hiv</B>:ab) OR (<B>'hiv-1'</B>:ti OR <B>'hiv-1'</B>:ab) OR (<B>'hiv-2'</B>:ti OR <B>'hiv-2'</B>:ab) OR (<B>'human immunodeficiency virus'</B>:ti OR <B>'human immunodeficiency virus'</B>:ab) OR (<B>'human immuno-deficiency virus'</B>:ti OR <B>'human immuno-deficiency virus'</B>:ab) OR (<B>'human immunedeficiency virus'</B>:ti OR <B>'human immunedeficiency virus'</B>:ab) OR (<B>'human immune-deficiency virus'</B>:ti OR <B>'human immune-deficiency virus'</B>:ab) OR (<B>'acquired immune-deficiency syndrome'</B>:ti OR <B>'acquired immune-deficiency syndrome'</B>:ab) OR (<B>'acquired immunedeficiency syndrome'</B>:ti OR <B>'acquired immunedeficiency syndrome'</B>:ab) OR (<B>'acquired immunodeficiency syndrome'</B>:ti OR <B>'acquired immunodeficiency syndrome'</B>:ab) OR (<B>'acquired immuno-deficiency syndrome'</B>:ti OR <B>'acquired immuno-deficiency syndrome'</B>:ab)</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>(<B>random*</B>:ti OR <B>random*</B>:ab) OR (<B>factorial*</B>:ti OR <B>factorial*</B>:ab) OR (<B>cross?over*</B>:ti OR <B>cross?over</B>:ab OR <B>crossover*</B>:ti OR <B>crossover*</B>:ab) OR (<B>placebo*</B>:ti OR <B>placebo*</B>:ab) OR (((<B>doubl*</B>:ti AND <B>blind*</B>:ti) OR (<B>doubl*</B>:ab AND <B>blind*</B>:ab))) OR (((<B>singl*</B>:ti AND <B>blind*</B>:ti) OR (<B>singl*</B>:ab AND <B>blind*</B>:ab))) OR (<B>assign*</B>:ti OR <B>assign*</B>:ab) OR (<B>volunteer*</B>:ti OR <B>volunteer*</B>:ab) OR (((((<B>'crossover procedure'</B>/exp OR <B>'crossover procedure'</B>) OR (<B>'crossover procedure'</B>/exp OR <B>'crossover procedure'</B>)) OR ((<B>'crossover procedure'</B>/exp OR <B>'crossover procedure'</B>) OR (<B>'crossover procedure'</B>/exp OR <B>'crossover procedure'</B>))) OR (((<B>'crossover procedure'</B>/exp OR <B>'crossover procedure'</B>) OR (<B>'crossover procedure'</B>/exp OR <B>'crossover procedure'</B>)) OR ((<B>'crossover procedure'</B>/exp OR <B>'crossover procedure'</B>) OR (<B>'crossover procedure'</B>/exp OR <B>'crossover procedure'</B>))))) OR (((((<B>'double-blind procedure'</B>/exp OR <B>'double-blind procedure'</B>) OR (<B>'double-blind procedure'</B>/exp OR <B>'double-blind procedure'</B>)) OR ((<B>'double-blind procedure'</B>/exp OR <B>'double-blind procedure'</B>) OR (<B>'double-blind procedure'</B>/exp OR <B>'double-blind procedure'</B>))) OR (((<B>'double-blind procedure'</B>/exp OR <B>'double-blind procedure'</B>) OR (<B>'double-blind procedure'</B>/exp OR <B>'double-blind procedure'</B>)) OR ((<B>'double-blind procedure'</B>/exp OR <B>'double-blind procedure'</B>) OR (<B>'double-blind procedure'</B>/exp OR <B>'double-blind procedure'</B>))))) OR (((((<B>'single-blind procedure'</B>/exp OR <B>'single-blind procedure'</B>) OR (<B>'single-blind procedure'</B>/exp OR <B>'single-blind procedure'</B>)) OR ((<B>'single-blind procedure'</B>/exp OR <B>'single-blind procedure'</B>) OR (<B>'single-blind procedure'</B>/exp OR <B>'single-blind procedure'</B>))) OR (((<B>'single-blind procedure'</B>/exp OR <B>'single-blind procedure'</B>) OR (<B>'single-blind procedure'</B>/exp OR <B>'single-blind procedure'</B>)) OR ((<B>'single-blind procedure'</B>/exp OR <B>'single-blind procedure'</B>) OR (<B>'single-blind procedure'</B>/exp OR <B>'single-blind procedure'</B>))))) OR (((((<B>'randomized controlled trial'</B>/exp OR <B>'randomized controlled trial'</B>) OR (<B>'randomized controlled trial'</B>/exp OR <B>'randomized controlled trial'</B>)) OR ((<B>'randomized controlled trial'</B>/exp OR <B>'randomized controlled trial'</B>) OR (<B>'randomized controlled trial'</B>/exp OR <B>'randomized controlled trial'</B>))) OR (((<B>'randomized controlled trial'</B>/exp OR <B>'randomized controlled trial'</B>) OR (<B>'randomized controlled trial'</B>/exp OR <B>'randomized controlled trial'</B>)) OR ((<B>'randomized controlled trial'</B>/exp OR <B>'randomized controlled trial'</B>) OR (<B>'randomized controlled trial'</B>/exp OR <B>'randomized controlled trial'</B>))))) OR (<B>allocat*</B>:ti OR <B>allocat*</B>:ab)</P>
</TD>
</TR>
<TR>
<TD>
<P>#3 </P>
</TD>
<TD>
<P>
<B>#1</B> AND <B>#2</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>#4 </P>
</TD>
<TD>
<P>
<B>'mother-to-child transmission'</B> OR <B>'mother to child transmission'</B> OR <B>'adult-to-child transmission'</B> OR <B>'adult to child transmission'</B> OR <B>'maternal-to-child transmission'</B> OR <B>'maternal to child transmission'</B> OR <B>'breast milk transmission'</B> OR <B>'breast-milk transmission'</B> OR (<B>'vertical transmission'</B>/exp OR <B>'vertical transmission'</B>) OR <B>'vertical disease transmission'</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>#5 </P>
</TD>
<TD>
<P>(<B>'breast milk'</B>/exp OR <B>'breast milk'</B>) OR <B>'breast milks'</B> OR (<B>'human milk'</B>/exp OR <B>'human milk'</B>)</P>
</TD>
</TR>
<TR>
<TD>
<P>#6 </P>
</TD>
<TD>
<P>
<B>pasteurisation</B> OR (<B>'pasteurization'</B>/exp OR <B>'pasteurization'</B>) OR (<B>'heat treatment'</B>/exp OR <B>'heat treatment'</B>) OR (<B>'sterilisation'</B>/exp OR <B>'sterilisation'</B>) OR (<B>'sterilization'</B>/exp OR <B>'sterilization'</B>) OR (<B>'decontamination'</B>/exp OR <B>'decontamination'</B>)</P>
</TD>
</TR>
<TR>
<TD>
<P>#7 </P>
</TD>
<TD>
<P>
<B>#5</B> AND <B>#6</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>#8 </P>
</TD>
<TD>
<P>(<B>'infant feeding'</B>/exp OR <B>'infant feeding'</B>) OR (<B>'infant nutrition'</B>/exp OR <B>'infant nutrition'</B>) OR <B>'infant feeding options'</B> OR <B>'exclusive breastfeeding'</B> OR <B>'exclusive breast-feeding'</B> OR <B>'exclusive breast feeding'</B> OR (<B>'formula feeding'</B>/exp OR <B>'formula feeding'</B>) OR <B>'early weaning'</B> OR <B>'abrupt weaning'</B> OR <B>'wet nursing'</B> OR (<B>'milk bank'</B>/exp OR <B>'milk bank'</B>) OR (<B>'milk banks'</B>/exp OR <B>'milk banks'</B>) OR <B>'expressed breast milk'</B> OR <B>'expressed human milk'</B> OR <B>'replacement feeding'</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>#9 </P>
</TD>
<TD>
<P>
<B>#7</B> OR <B>#8</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>#10 </P>
</TD>
<TD>
<P>
<B>#3</B> AND <B>#4</B> AND <B>#9</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>Cochrane CENTRAL Controlled Trials Register:</B> <B>Date range: 1 January 1980 - 15 July 2008</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P>(HIV INFECTIONS) OR HIV OR HIV OR HIV-1* OR HIV-2* OR HIV1 OR HIV2 OR (HIV INFECT*) OR (HUMAN IMMUNODEFICIENCY VIRUS) OR (HUMAN IMMUNEDEFICIENCY VIRUS) OR (HUMAN IMMUNO-DEFICIENCY VIRUS) OR (HUMAN IMMUNE-DEFICIENCY VIRUS) OR ((HUMAN IMMUN*) AND (DEFICIENCY VIRUS)) OR (ACQUIRED IMMUNODEFICIENCY SYNDROME) OR (ACQUIRED IMMUNEDEFICIENCY SYNDROME) OR (ACQUIRED IMMUNO-DEFICIENCY SYNDROME) OR (ACQUIRED IMMUNE-DEFICIENCY SYNDROME) OR ((ACQUIRED IMMUN*) AND (DEFICIENCY SYNDROME)) OR (VIRAL SEXUALLY TRANSMITTED DISEASES)</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>(MOTHER-TO-CHILD TRANSMISSION) OR (MOTHER TO CHILD TRANSMISSION) OR (ADULT-TO-CHILD TRANSMISSION) OR (ADULT TO CHILD TRANSMISSION) OR (MATERNAL-TO-CHILD TRANSMISSION) OR (MATERNAL TO CHILD TRANSMISSION) OR (BREAST MILK TRANSMISSION) OR (BREAST-MILK TRANSMISSION) OR (VERTICAL TRANSMISSION) OR (VERTICAL DISEASE TRANSMISSION)</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>(BREAST MILK) OR (BREAST MILKS) OR (HUMAN MILK)</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>PASTEURIZATION OR PASTEURIZATION OR (HEAT TREATMENT) OR STERILISATION OR STERILIZATION OR DECONTAMINATION</P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P>(#3 AND #4)</P>
</TD>
</TR>
<TR>
<TD>
<P>#6</P>
</TD>
<TD>
<P>(INFANT FEEDING) OR (INFANT NUTRITION) OR (INFANT FEEDING OPTIONS) OR (EXCLUSIVE BREASTFEEDING) OR (EXCLUSIVE BREAST-FEEDING) OR (EXCLUSIVE BREAST FEEDING) OR (FORMULA FEEDING) OR (EARLY WEANING) OR (ABRUPT WEANING) OR (WET NURSING) OR (MILK BANK) OR (MILK BANKS) OR (EXPRESSED BREAST MILK) OR (EXPRESSED HUMAN MILK) OR (REPLACEMENT FEEDING)</P>
</TD>
</TR>
<TR>
<TD>
<P>#7</P>
</TD>
<TD>
<P>(#5 OR #6)</P>
</TD>
</TR>
<TR>
<TD>
<P>#8</P>
</TD>
<TD>
<P>(#1 AND #2 AND #7)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-10-23 15:54:00 -0700" MODIFIED_BY="Tara Horvath"/>
<FIGURES MODIFIED="2008-12-03 11:15:41 -0800" MODIFIED_BY="Tara Horvath">
<FIGURE FILENAME="flow1.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2008-10-30 16:52:47 -0700" MODIFIED_BY="Tara Horvath" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flowchart of screening process</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAikAAAOaCAYAAABdusJxAACAAElEQVR42uydyXIdSW+2fUeO8CU4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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2008-12-03 11:15:41 -0800" MODIFIED_BY="Tara Horvath" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias table. Green = low risk of bias; red = high risk of bias; yellow = bias risk is unclear.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASsAAAG8CAIAAAAJpRQYAAATg0lEQVR42u3dvW5cVRfG8ZHSULhI
kSvINbiKrBQoHfdEShdIocxdRLkEFKAEKiqkEBsRFxRO0gGJzjvGr5Cxz5nZM3PW/jq/RyNkJsnj
8fL+7732x9lrtSKishqIqIQQSIRAIgQSEQKJEEhECCRCIBEhkAiBRIRA6q7lLb7tiQKVaXajXyOQ
KDeB/7bCZdKIQCpPoDFQOKhMyxMHBBIhkAiBRLmbnYfFEUjF29/o1wgkyorfYiFEICEQgWRCuNR2
iEAiBBIhkKhgFjpYCyXK3/imvkAgEQIRSAhEIFGGeaDdCCJCIBECiYpMBWWhRMXwu/UFAokQiEBC
IAKJotvfYvFDIBECiRAoEFR8KigLJSqG32KnggjMHmvRRiACC7a2QdUEBCKwLIHDsqsFjcZhsBtB
OQkkQmDJ/p4IgVRN+3NTk6ZABTNzKzEILNDr25xAIAKLtTlCIAIRWF1GYB5ICCQELmkSaB6oSSCQ
EIhAkhGoI0/5m52AaA/aQcm8S/A1CQQisIr8UxZKCCwZEPuBZB6oP0IgIRCBRDICBHbY31t7IAQS
IdDMZ8Ezn8FuBAK1uQq7JPNAKjAGisbC44NAQiACl52OiobdCATm7vVdmE0ILE8gCAmBCJSTI3Cp
EMIvIidvC2YEUlcZQXMbjAgs0+YoA4FDC1XiEIjArnLy5iKMwMILD4IfFGQEEhECiRBIo4moaWHm
bL/OaCOw2MJDoysHzYW68mgjEIF1DVaz43fzHQQiEIGT0ZgxFAik1F5ffxTUH43GGYFEMgIEUpUQ
ekKXWl17kNPmiTMC++nygzzb+lXG3RPjVBqVIXBo4WmAIf7uRgRSMQIXHg0E0s59/1y2whsdZwRS
/6gsNAKaQn/5bf2/Vnc3IrBkrz9Xm2u3IkXcLRWyUMrX5ppbe8gQDWMgaXM7ByTDyWwEIjDfWWSV
CWWhtL2JxPX6ejpZKGlzZUYqBBICd/7Yy8wIEFhF3x/k3FyvMXvpCPNASur1F7tqYjaLwCra3GJ/
BRZvEdgPgW4ibZFtBFbRMmasGWSvf7AjTwXbHAIRSAhEIALlt6JhHkiUyMng+UAimTMC9fqz5V3L
fEJXFkpl2pwndDdHw0oMITDfSIVAQmAtoR6auLzYL6z1Xn/wjPzGUFQbEwR22OU3jcpCOwstGIE+
MwLNT5bVoEM/cMSuT+DcARil2twCnwrPQGDcXcCzf3IEdkJg2zlY2E1NQQQO81WJQ2DhNqc/anEM
lIXSlvxz4VloUE8XEVUEUrcQttSBagqtz3y6Gb2XBjYCu827PCOfYZI5y/QSgR2uPVjjaWWVFYF9
EtgKhM0N2gjUN/dDYAeVtxFIUfMTBG5mZq4PjEBCYAVpkdaQPxEd7IY5IYTA1mcR2M4fjXln8gjs
hEA3/xWJs3mgltE2gdE1dOuPMwI7mfnYjUAgWdWohcAh+Easm99CFkp6jfYjoCkUaXCCHxpnBNLO
aViFqxqNZqHD3Bcr/bv4aTcChAVac4ZcIK4p1tzIEYjATlKA6DEQgX3OA61qNDfozRtnvy2qKxdd
2twVgdRVUhq0XoLAnnv9uX4FHexzLPAkHQLb/v211Xaz/RQR61JBvScC255FNE1gnkSg8owAgQg0
pUTggqeCoTNM0UYgUYH+aFBHnqiqnLzabB+BxXr9Ifj+EgQikCZ/f3HPbje0GtHiE7p2IxDYD4GD
s6wIRCAhcKHzQM9GtD7fHpxKIyqVa7grjQiBdNivcOH3xCAQgR22jLYgbHF31DPyCOyEQLUuENhV
m1MRGoGUGnGztSACMzwf6EwMdTcCtHyW1RhIhECiOVpzExWFQ1ZWtQYqmHzG3SlY/wwTgT0366Vl
dKEExv7WNN/8nAwt3FbY6DnvhvZdEdhty5jXMwPhlZ+JkYUisCSBw42dzPqrvTeUOSOwHwJnnwdm
qC7WHIHmgb2tlzTxaVskMPQZFCezSX9US7ZvHthkFhqR6bmlAoG02zyt5rp2Wz85AhHYwxjYyui6
oXFX2B8Nkc+gmAdS7jFw9B3NZk6eBaJgOtrKqgYCEdjbCkErkR9lO+KgCQKp1RUCmXP+mTYCEfif
4bSDZyNmjEbQp3UqrSsIG81Co1dZZ/+00YezEUhNVqiP25NoKBdFYC9T+Yx7/YTArmipf6TqINTV
OiOwrtRxUb1G3AyzofrYCOwHQvfEIJCKtcIW9/oRiMDyGd3sba6hncbQhmceSGXGk7ZO2zSXOUdF
QAvuDMKFZ6EIpNQuv+a+304jAnseqYamno0I+szaHgIL512Vn7Ecst9/gUBqksAWnfOk0EPYLRXD
jAVhsFFqctXK6Ko+dpAzArHdc3+EQKKSmTMCKd/8JNtI1cQM05kYyto355xhNjF3baxHxkY3KwRx
GZ25KwIR2BuBLWb7diM6mQe2shvR9C1sVmKoebbzoDKEFQ9EIFGxzBmBtCmXqzz4+Z/QtRtB7eVd
LbLddOYcEgFgtJ53UZ6ourEXgTJnBFJNeVdPWWj9OyjqRpBc0TyQZo1+zc63zn+0cuIUgZTarGt2
nlq2rfm8mwqelDqe1O+cgcDQumVxl0rNv28Jj8xznrhcriECo+OMQDIGIhCB5oGzZolzHsXijMAa
UGzLmazEECGQiBBIhEAiQiARAoWSaNcdCwTOSSBnzrs6I1DL4IxABHJGIGkZnBGIQM4IJC2DMwL7
I/Dvy8uz09OfTk6+u3//m9Xq26OjH46Pf3369K8//lig8+Xfl6dnpyc/ndz/7v7qm9XRt0fHPxw/
/fXpH38tyxmBmQj8/fnz7x88WDfiu6914/7t668X5fz89+cPvn+wGrNeN+6vf1uQMwJzELgeNEbb
8c3X+u8sxHk9aKy2Wa//zkKcERhO4Hok2dqUr19To0pPzuuRZJVmPTWq9OQ8M4GZL4rdo3jN6CdM
fHPrIaPRN9fzqKlEbjS1+/PiomPn9TxqKpEbTe0u/uzZeWYC898jsut3Gf2E6W9u/dajb56dniY2
5Q15XTfOp2enq12sR/O6bpznJHBzOYSUQWaKhKl/uAGYlJ/oEAKnzEff/+nkZKfW/MPxccfOJz+d
jPz7a41ZH//Qs3MsgbuOPCnv3IVz17HrcAITf9J/db2In/769uioY+frRfz01nz0bc/OdRE4Ct4e
wOz9kYIInPrdraZ/iR07b/Eds+7YuQEC7658pLilPJGVjUBjoDGw8DxwbwL3WDhJyUI3ELXVJzGz
NQ80D6xoLXTvJr51yreBwPQNg2gCrYVaCy2/H7jTLtzmZc/EtdAp2EZz1L0/nv1A+4EV7QeSMzEp
zs7EIDA3gYNzof+Vc6EIzE3g9agytca4fv/8q68W5bweVcbXGP9J5L46X5AzAjMROEw/azc6j+re
eepZu9F5VMfOCMxHIGfOCEQgZwQikDNnBGoZnBGIQM4IRKCWwRmBfRBIpHaSMZCzMRCBnDkjEIGc
EYhAzpwRiEDOCEQgZ84ILEngp0+X796dXlycnJ/ff/NmdXZ29Pbt8eXl00+fVDhSO4mCCfzw4fn5
+YM1eHdfayDfv1fhSO0kCiNwPdCNsnfztf47ezh7kr11ZwSGE7ge/bbid/2aGgnd5tKrcy0EJp7f
OZyHQ2onDduKUoy+v5773Uw+X71aPX68+uyzq9cXX6x+/PF2OvrxoxvN3JXW0Sri1Hc55F7gYZd7
8t+9O73J2MOHV9F++XL14sXVF48eJeWibvXs0rkBAlOurB/GjkQPYZVbdn3z4uJkNOH85Zerz7ke
CW+9//atm63dmV0HgYnVlIZdyrnkJ/B64+HW6+efV59/vrp3b/Xs2e0/OjtT3UHdiKLzwBRg7v53
JwIPqdwy7Fg/cHQAfPLk6if98svx9ZhEZxWOWnduKQtNJDCxxkNOAkfHwPXot9br1yP4GQONgfVm
oZsJTKzxcEjtpGH36mVT88Cpl3mgeWB1BN4ttJIy6FVSO+nWWuj161rp+/LWQq2FlsxCh+QKZ5vX
Qg+snbR10zJlP3AzgfYD7QfS/P2IMzGcEViSwMG5UM4ILEvg8P9nI+5PPxuhwpHaSRRJ4DD9fODo
3G8nZxWO2nVGYD4COXNGIAI5IxCBnDkjUMvgjEAEckYgArUMzgjsg0AitZOMgZyNgQjkzBmBCOSM
QARy5oxABHJGIAI5c0ZgSQLjavrE1U5SlSnaGYGZCIyr6RNXO0lVpgzOCMxBYNwT1nHPyHv6Po8z
AsMJjLtlJO6eGDfQ5HGui8D0u3H3njTnr50Ud9NW3F1pbmHL41w7gXtczpnun612Utxtk3H3hbqJ
NI9z1QQmXiw/eplvyk+UjcC4G5fj7sx2G3ce53oJTLxY/u7fnyp1VpDAuKoDcXUjVKTI41wpgYdc
LB9duWWPeWBc5Z242kmqMuVxrpHAzQXJyhJoDDQGLmIMDIUkFG/zQPPATuaBU01/a0XrPSCxFmot
1FrodjzuJqj7Vd48pHaS/UD7gWonVS1nYspGw5kYBDoXWjgazoUicFJxNX3iaiepypTBGYGZCBwi
a/rE1U5SlSnaGYH5COTMGYEI5IxABHLmjEAtgzMCEcgZgQjUMjgjsA8CidROMgZyNgYikDNnBCKQ
MwIRyJkzAhHIGYEI5MwZgSUJVDspTzTUTkLgiNROyhMNtZMQOCLPyOeJhmfkETjed7onJkM0er4n
ZqeqRjUvgaidVNbZXWnzEFjbmJn4edROKu7svtAZCNyjqtHWm3aHO1eDplREGr3lfutB2MwEujM7
TzQ6vzP7kKpGd8nc8M93KpOUjndBAtWNyBONzutGHF7VaHSQvOsczcNOn3D0a7WT1E4qUDvp8KpG
6QTefaRqP0jUTjIG9jYGHj6A7DQGRkAyqJ1kHtj0PPCQydjeX29+c2sx3fRtFWuh1kIbWAudauuz
ELhhLXQq4Ux5c0OKaz/QfmAD+4F0yLakMzF5oqF2EgKdCy0cDedCETgptZPyREPtJAROSu2kPNFQ
OwmBnDkjEIGcEYhAzpwRiEDOCEQgZ84IRCBnBPZMIJHaScZAzsZABHLmjEAEckYgAjlzRiACOSMQ
gZw5I7AkgWon5YlGnPOnT5fv3p1eXJycn99/82Z1dnb09u3x5eXTT5/UTqqeQLWT8kQjzvnDh+fn
5w/W4N19rYF8/17tpIoJ9Ix8nmjEOa8HulH2br7WfweBNRLonpg80YhzXo9+W/G7fk2NhNURmFiM
aY8PtvXqUbWTCjq3eKPZeu53M/l89Wr1+PHqs8+uXl98sfrxx9vp6MePF20QmFKP6RACN/+R2klF
nFu81fPdu9ObjD18eNV0X75cvXhx9cWjR0m5aKVjYPpFoImFHG7+byWVW9yZnScacc4XFyejCecv
v1x5r0fCW++/fXvcNoHp93Bv/ec1EKhuRJ5oxDlfbzzcev388+rzz1f37q2ePbv9R2dnR80QuJWc
PVp/CoE5K7eonZQnGnHOowPgkydXll9+Ob4e09hKzN4FzIaxSkm1EWgM7HIMXI9+a71+PYJfY2Pg
MHcJwa0Eqp1kHjjLPHDq1dI8cHRpNL0oUmKR3fRdEGuh1kK3roVev66Vvi/f2H5gelGk0VVTtZPs
B8btB24msJn9wC7lTEzZaDgTg0DnQgtHw7lQBE5K7aQ80Yhz/ufZiPvTz0aonVQ3gYPaSbmiEec8
9Xzg6NwPgdURyJkzAhHIGYEI5MwZgVoGZwQikDMCEahlcEZgHwQSqZ1kDORsDEQgZ84IRCBnBCKQ
M2cEIpAzAhHImTMCSxLYVk2fa6mdFO2MwEwENlfTZ1A7KYszAnMQ2OKz256Rz+OMwHACW7y/xD0x
eZxLErjhst0N/zt12Ce9GFM3tZPiavq4Ky2Pc0kCp+ja6Z27P8bmn7mz2klxNX3cF5rHuSUCE2/C
3gpJfgJbrOnjzuw8zhURONXcOyCwxZo+6kbkca5uHpg4GG6eB8ZVbtlvHthiTR+1k/I4V7QWOjX0
DRvrumyGqvvaSXE1fYyB/Y+BU6smGQjspnZSXE0f88DFzQM3N+6U2d2GYkyhC6T1rIXOWNPHWmj/
a6FT88AhrazSfvuBndVOiqvpYz+w//3ALuVMTNloOBODQOdCC0fDuVAETqq5mj6D2klZnBGYicCh
tZo+/84J1U4KdUZgPgI5c0YgAjkjEIGcOSNQy+CMQARyRiACtQzOCOyDQCK1k4yBnI2BCOTMGYEI
5IxABHLmjEAEckYgAjlzRmBJAtVOyuMcFw21kxomUO2kPM5x0VA7qWECPSOfxzkuGp6Rb5hA98Tk
cY6LxlLuiZk6y5N+NWD6t5jxzc0fSe2kPM5x0VjiXWlb7y883FbtpA3OcfeFxjnHRaPb+0J3JXC0
wsTU0JR+cf1+BKaPgWon5XGOi0afd2bvSmBihZZbBV5SvsWuBO6ahaqdlMc5Lhrd1k7aLwtNJ3DX
dHQnqlcVVAtqsXZSnHNcNBZRO6kVAveYB6qdVHAMnCUaxsCZCVQ7aVHzwMOjYR44J4FqJy1kLXTG
aFgLTeJhw0rp1H5jZ/uBTdROyrYfOGM01E5qRs7ElHV2JgaBzoUWdnYuFIGTUjspj3NcNNROapvA
Qe2kXM5x0VA7qW0COXNGIAI5IxCBnDkjUMvgjEAEckYgArUMzgjsg0AitZOIGuy4BYIIgUQIJCIE
EiGQiBBIhEAiiiWQiErpf0W2mMPa0p6rAAAAAElFTkSuQmCC
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2008-12-03 11:15:41 -0800" MODIFIED_BY="Tara Horvath" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>A plot of the distribution of judgements (Yes, Unclear and No) across studies for each risk of bias item.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfMAAADnCAMAAAA94U9AAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAAJAUlEQVR42u2dC5OjKhCF3a1U9f//uV01O3PvxAdvBKIJynf2kUQB
kWM3tPGkpwmMhj+TMAhjQf8yBsMBzuEcwDmAcwDnAM4BnIP+8BjiLBWirXtvY3B+YXdW0vN/BWV+
8O3M5wDOAZwDOAdwDu7KuRaGu++NhjV2QFVC8iM4V+l1HCXsqgikH+fbFwtaLOn//xdD03XjvGUz
tK1gqvxvBTUt2zWjhZZP1tHCUiCD6vtwKvMQy/xWbMc6b5R5+/OfXTBVftshk19TY4XcJsU5zLKd
Z/yOsfPfodSIK5WMj41tl8x+yVQMjirZQym8H2Dnur9Q0/Dd73Ui++Uz25LH1fwVCl7nXJxRlsRA
q797cbpStPiKbUu5FRW+MDvXtz8NZ3bu6tiZTpGXYHeqvMuaJoJC3fMmRVcTaFzD/U/7013PLtt8
sl6eK6t12E3BaHnbIahVcEoXWj+Zo01+KXx7DgfoWGqHt6b8QdQp35//mNVtx89MKC66E9/++tQp
J7Wbw/dlCfrukvMLAHfRdk8GwDmAcwDn4Mbr9guAW7QDahqOO81/Fx0BNA3M5wDOAZwDOAdwDuB8
C4k1GRrra0Gz7uxD0/ABzgsEECd+2YWm4eO+XQPNQlKJ4AkXQq3DZsHz3rC8ctdtB++4D+fLFlJK
hCkuXHC2GcnDrHkIywuahs/YuRFA+O5895nnmEZCUnuT8goegny/nWvT8qugxUJtBJS/n/Ok3qBZ
iSCZ6hD8ed9uCSAi9qjVHkL3qytXQU9rOEvPsKNECHQNwba1euwA3poRJDBGbg7l+3NL08C9V3z7
TfEF06NxzuR+/rodwDmAcwDngDXc4fE5RJOnIYqfO48AmgbmcwDnAM4BnAM4B3B+Soit6wPN4S+B
kqehCteJz58/Di3ru2CXSzlPytzMt2sgd3A2YOG3sfPAkt20D84GTPwenLtcGrmDxjfg2m81nxf6
AUCsBu7CeSJ9C2Z+v/l8m7tdhcO2Ad+exg01DRG6le/Pr5Gn4ShnAG4Sn2cW9zF8w/RtOa+8FFi3
AzgHcA7gHLCG6zuEGx1oGm6Fn7oy+HbmcwDnAM4BnAM4B9fivDiK1ZIqB7amVS2Sp2EH94zP0TRU
cK7zj6tO6//P32d+blPzdrWm343zA+X2tmXAdf1N/UgzThXJt2ZKzA++miKJF6iutfNIagQrIYKT
UGHJiWBsyrEuyTTjVNF8a6aEmv7lXnhUpnYNF0mNYCdEqB7MbF6FyObMu4hWLdYrMe4dHDufF63j
itd3WtPu8jTz9uPeq2/3Z3RwMOfRFCkN1m/WXMl3idrLLGBewIvxeUE2hLRJFhtrLBDTRIymbu1w
q53GgUug1s5j6RKsHZPlUsWU8lIpPHdFm3GqPD84VTSyy1IvuE49eEHTsIc6TcNVR1L5/pw8Dfj2
5rXXZYCm4Yh1+6XA5F60bgdwDuAcwDlgDddXfA7RaBrGO7svfDvzOYBzAOcAzgGcgyE5X/Mo5Mvs
Rs5aHUyTp6EWx8Xn+99dFT5xIa8fGk3DO337M02CrjkT1Da7NYNCfO/sBXT5M1nNOI2afAzbJyVP
w6fs3JiYKzOYbMnCNKX2zn/Fsk7LWD1lhP/JFEHT8FY7X6yyaLglv3kWPsXLS6IhX4yBa3/vfJ7V
kYYihB056k6pl9YOcH4w/WlrdkUIUuQNILH3+Dxt6hp7q+7nbVoPTV3LjswV8l4795RknqohtXdV
QfsFvU+hTsJ242gaCnC1PA3adBtA+f78izwN+PbrQNp231vT8H1vzk+5Uli3AzgHcA7gHLBu7zSE
Gx1oGoY7OzQNzOcAzgGcAzgHcA7gfD9erhRApJQOyadx0DRk8KH4/DABRLw1NA3d+vZSAcSicnDF
DJY3sDKwYODd2rmxxxIBhETFDFYDvlICE++Qc02mbSh04P7j1IHqAdfe8Xxel0hrRwCxPQ8L5b36
9pjFtq3+1qwOLN4uEp+3m7qXu8FSRUBtv3ZeJICwU3i5c7cGCR/w7Xv4M4RFoGmwNQ3ce8W33xRo
GobjnMm9u3U7gHMA5wDOAZwDOAdwDuAczgeAfrh+Xw1g59g5gHNwPwzy/TlET7f9TcDdE268Zl41
jA4awLcznwM4B6zhwJ0WtI9RTnRNCFIherCSiEhlVbNukrZjm3WXFPdgUe5tvU4ddBDObZFjMeXr
aK0PzJdXdcKFlmOb6jqV9kC9M00elPl8L75rj5KO0FWUK+nLj/YYjspqJrSZfvVvDNQfW4p7IMUn
PBbns8JJi9etq2v/lbRXVp0mTzDZ0oDTTlMPYnUGs3OZ7NyLNS6+oaq8fOxXexCvM9x8XjNi+qJn
fn1akddXCGEd1nAFk2l7fHhUnMk9mfb4fPltAikeammqGgT4rQ1ITedj8XmkjnIfbjz3hW8fD3AO
5wDOAZwDOAfXw+O80B/0BYlwTqR+77Ac3858DuAcwDmAc3CPWC0TtfWyoqdjp3HuW/93r9396qZj
f9yPP/h2AOfgEpxrfN6aN2rBRBeUUSuZhu7Nj9U96+BOcrRjGp6yvnnEijmX5/FiS5Psw5g5dZWk
i8ktbv5rbrDkYyNW79tTCQuXjIdWLhzdEiCqe+XbiRIPzISoW6rFWFf1/aYvXkcCe9WlU6rGCZw/
Yo+KExAriaGb93CKC6ucFIdTNFFiMhNi46PcJtti0NXPpeXxRsDuoDpj8J4R+1tz1cquF/oVyjz/
eQXSuZDSmRAb7CragHwuZI47XPHfS2TXiSP2aPCg69lI+YlLwSqjuuHS+fSDa4Mmd3X2iD1ajanC
WS5Fd5RWJ2RCFKfhC+HcEfvbaD+aubC9i1uL17baZJSRiEJLQswPevedwTl5xB6NfsfOeyh5D+MX
dUsmMiFWKUfTuRWXrspnSQ8Gy+qpvn/ELO2SJjPtfcveqvSUpW5kq3+/vZvvWPz77VJ6XoeN3l5D
2/4jfkNITiD9tulOncHSA6OJihE74jcHTuDnvo9jyklnWdFWnPNuU01+9dqxnwtddo9LWRkdOwJ8
lzoe4BzOAZwDOAdwDq4HO1ZDjDwc50iR8e0AzgGcAzgHcA7gHMA5AOBN+A9/2O5QWlZ17QAAAABJ
RU5ErkJggg==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>